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Solubility behavior is one of the most challenging aspects for drug commercialization and often the main
reason of drug that do not reach to its full potential. Now nearly 60% new chemical entities possess
solubility problems, whereas practically no drug products with less than 10 µg/ml solubility in 70’s or 80’s.
There is an ever increasing need to develop new formulation techniques and exicipients with novel
mechanisms of action. Various techniques have been applied to enhance the drug solubility such as cosolvents, particle size reduction, lipid based drug delivery systems, nanosuspension, use of surfactants,
salt formation, cyclodextrin complexes and solid dispersion etc.
Chapter 1 is an introduction into biopharmaceutics classification system (BCS) and novel drug
solubilization techniques. It provides a brief history of the BCS and its application in drug development. It
also looks into the recent poorly water soluble drugs approved by the Food and Drug Administration and
the formulation techniques that these drugs used.
Chapter 2 is a brief history of solid dispersion, including its theoretical basis, preparation methods, and
characterization and quality control tools. Several drug products using solid dispersion technique are also
reviewed. This chapter is intended to combine recent literature on solid dispersion technology for
solubility enhancement with various preparation methods, evaluation parameters and commonly used
polymer carriers.
Chapter 3 explores the applicabability of a cold water soluble modified starch, octenyl succinic anhydrate
starch (OSA starch) as solid dispersion carrier to increase the aqueous solubility and dissolution rate of
poorly water soluble drugs. When using OSA starch in solid dispersions via spray drying techniques, the
hypothesis is that drug is dissolved in the starch solution, when water evaporate via spray drying, drug will
be solidified together with starch and mostly the drug is in amorphous form because the rapid spray
drying process (seconds) prevents drug crystallization. In this system, the starch is homogenously
distributed in the matrix and thus prevents drug crystalline growth as a characteristic of the polymer.
When drug is dispersed in starch solution, the starch will encapsulate drug particles to complete the
microencapsulation process and micro-scale drug particles will be retained in the starch matrix. These
properties will be helpful in enhancing drug solubility and dissolution rate.
Chapter 4 explores a solid dispersion of furosemide and sulfobutylether-β-cyclodextrin which was
another derivative excipient of starch. Solid dispersion preparation method and mechanism are also
discussed. The work serves as a positive control for OSA starch solid dispersion. Comparison and
contrasting the two solid dispersions assist in the interpretation of OSA starch solid dispersions.
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ABSTRACT
Solubility behavior is one of the most challenging aspects for drug
commercialization and often the main reason of drug that do not reach to its full potential.
Now nearly 60% new chemical entities possess solubility problems, whereas practically
no drug products with less than 10 μg/ml solubility in 70’s or 80’s. There is an ever
increasing need to develop new formulation techniques and exicipients with novel
mechanisms of action. Various techniques have been applied to enhance the drug
solubility such as co-solvents, particle size reduction, lipid based drug delivery systems,
nanosuspension, use of surfactants, salt formation, cyclodextrin complexes and solid
dispersion etc.
Chapter 1 is an introduction into biopharmaceutics classification system (BCS)
and novel drug solubilization techniques. It provides a brief history of the BCS and its
application in drug development. It also looks into the recent poorly water soluble drugs
approved by the Food and Drug Administration and the formulation techniques that these
drugs used.
Chapter 2 is a brief history of solid dispersion, including its theoretical basis,
preparation methods, and characterization and quality control tools. Several drug
products using solid dispersion technique are also reviewed. This chapter is intended to
combine recent literature on solid dispersion technology for solubility enhancement with
various preparation methods, evaluation parameters and commonly used polymer
carriers.
Chapter 3 explores the applicabability of a cold water soluble modified starch,
octenyl succinic anhydrate starch (OSA starch) as solid dispersion carrier to increase the
aqueous solubility and dissolution rate of poorly water soluble drugs. When using OSA
starch in solid dispersions via spray drying techniques, the hypothesis is that drug is
dissolved in the starch solution, when water evaporate via spray drying, drug will be
solidified together with starch and mostly the drug is in amorphous form because the
rapid spray drying process (seconds) prevents drug crystallization. In this system, the
starch is homogenously distributed in the matrix and thus prevents drug crystalline
growth as a characteristic of the polymer. When drug is dispersed in starch solution, the
starch will encapsulate drug particles to complete the microencapsulation process and
micro-scale drug particles will be retained in the starch matrix. These properties will be
helpful in enhancing drug solubility and dissolution rate.
Chapter 4 explores a solid dispersion of furosemide and
sulfobutylether-β-cyclodextrin which was another derivative excipient of starch. Solid
dispersion preparation method and mechanism are also discussed. The work serves as a
positive control for OSA starch solid dispersion. Comparison and contrasting the two
solid dispersions assist in the interpretation of OSA starch solid dispersions.
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CHAPTER 1.

BACKGROUND

1.1 Biopharmaceutics Classification System (BCS)
The Biopharmaceutics classification system (BCS) was introduced in 1995 by
Gordon L. Amidon et al. to correlate the drug in vitro dissolution performance to in vivo
bioavailability (IVIVC) [1]. Two primary parameters: solubility and permeability were
utilized as the basis for this drug classification system. In the system, four categories are
applied to drugs: class I, high solubility, high permeability; class II low solubility, high
permeability; class III, high solubility, low permeability; class IV, low solubility, low
permeability.
In the system, the definition of high solubility is that the highest dose is soluble in
250 ml or less of water over a pH range of 1–8 at 37 °C. Permeability is defined as
effective human jejunal wall permeability of a drug; the unit is 10-4 cm per second. High
permeability means no less than 90% extent of absorption and at the same time, these
drugs are basically stable in GI tract [2]. It is generally accepted that drug dissolution is
the prerequisite for drug absorption for any orally given dosage form based on human GI
tract physiological condition. For orally given drugs, passive transcellular diffusion is the
major mechanism for drug absorption [3].The mass of drug across the mucosal
membrane of intestine is the upper limit amount that ready to enter system circulation [4].
1.1.1 Relation between Do, Dn, An, and dissolution
Besides solubility and permeability, three dimensionless parameters are also
introduced to describe the relationship between dose, dissolution, drug solubility and
drug permeability [4]. They are absorption number (An); dissolution number (Dn); and
dose number (Do). Several equations are derived to describe the relation between those
variables. For absorption number (An), it equals the permeability of drug divided gut
radius and then times residence time or transit time of drug, see Equation 1-1.
Absorption number (An) = (Peff/R) • <Tsi>

(Eq. 1-1)

Where Peff is permeability, R is the gut radius and <Tsi> is the residence time of
the drug within the intestine. Dissolution behavior is complex, for dissolution number
(Dn), five variables are included in its equation: drug diffusivity, particle radius,
solubility, density, and residence time, see Equation 1-2.
Dissolution number (Dn) = (3D/r2) • (Cs/) • <Tsi >

(Eq. 1-2)

In this equation, D is the diffusivity of the dissolved drug, r is the initial radius of
the drug particle, Cs is the drug solubility, and  is the density of the dissolved drug; <Tsi
> is the same as in Equation 1-1. The concentration gradient of drug in gut is the original
driving force for its diffusion which decided its diffusivity. Generally, the concentration
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of drug in gut is several orders higher than that across the membrane. Decreased particle
size, increased solubility, prolonged GI tract residence time will increase the dissolution
number [5]. A higher dissolution number is in favor of increase of drug absorption. For
dose number (Do), it equals dose concentration divided solubility, see Equation 1-3.
Dose number (Do) =

/

(Eq. 1-3)

M is the dose of the drug and V0 is water needed to take the dose, generally 250
ml is set as default. Cs is drug solubility. For a given dose, increasing the water amount
to take the drug or increasing drug solubility will reduce the dose number which favors of
drug absorption.
By analysis and summarization of permeability and fraction absorbed of 18 drugs,
(see Figure 1-1) [1], the relationship between drug fractions of absorbed and
permeability is described as Equation 1-4.
Fa =1-e-2An

(Eq. 1-4)

In this equation, the assumption is that the drug is soluble in the GI tract. Basically, it
applies to class I and class III compounds. In this case, absorption number (An) and
permeability are two primary parameters to predict oral absorption. The absorption
number (An) can also be expressed as drug residence time in intestine divided by drug
absorption time. See Equation 1-5, which is derived from Equation 1-1. In Equation
1-1, the unit of Peff is cm/s which likes velocity; R is radius of gut, which likes distance;
since time equals distance / velocity, the time of drug absorption equals radius of gut /
permeability that is the reciprocal of Peff/R, too.
Absorption number (An) = <Tsi> / <Tabs>

Figure 1-1.

(Eq. 1-5)

Correlation between human permeability and fraction dose absorbed.
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When residence time (Tsi) equals absorption time (Tabs), absorption number (An)
is 1 from Equation 1-5, substituting An=1 in Equation 1-4, Fa is calculated around 86%.
Return to definition of high permeability, Fa should be no less than 90%. If calculating
An from Equation 1-4, it will be bigger than 1. The physical meaning of An>1 is that
drug absorption time is shorter than residence time. As long as the drug dissolves in the
GI tract, the drug will be absorbed. The above discussion is applied to BCS class I and III
compounds.
For BCS class II compounds, those drugs are poorly water soluble and GI fluid is
not enough to completely dissolve them. In this case, Equation 1-6 is derived to describe
the relationships between solubility, permeability, dissolution and drug absorbed [3, 4].
Since Fa always equals or less than 1, Do ≥ 2An.
Fa = 2An/Do

(Eq. 1-6)

The concentration of these drugs in GI tract is equal to their solubility. The
assumption of Equation 1-6 is dissolution rate should be faster than the rate of drug
absorbed across the intestine membrane. Dissolution rate is the limited factor for these
drugs oral absorption. For class II drugs, dissolution number (Dn) is commonly less than
one.
At a given absorption number An, the relation between Do and Dn can be
described by Figure 1-2 [1]. In Figure 1-2, An is fixed as 10 which means the drug is
high permeability. Dose number (Do) and dissolution number (Dn) decide drug fraction
of absorbed. From Figure 1-2, we can see that a low dose number and high dissolution
number nearly always gave higher drug absorption. The change in Dose number is
decided by water volume and solubility of drug. More water to take drug can decrease Do
but this tool is limited by patient compliance and stomach volume capacity; increasing
drug solubility can be a way; dose number is not commonly changed which is decided by
physicochemical properties of compound and also decided by its pharmacodynamic and
pharmacokinetic properties. For dissolution number (Dn), the higher dissolution number
will result in higher fraction of drug absorption. Some formulation strategies can be
applied: decrease particle size or increase dissolution rate. Two examples are shown in
Figure 1-2. For digoxin, the Dn is between 0.1~1.0, Do is around 0.4 and the fraction
drug absorption is around 0.4. Digoxin is a low dose drug, 0.5mg/dose, when particle size
is decreased sufficiently, the dissolution rate increased so that the tablets and its hydroalcoholic solution were bioequivalent. But for piroxicam, Do is around 12 and Dn is less
than 0.1, its Fa is less than 0.2. To dissolve the dose, 2857 ml water is needed. For this
drug, solubility is the limitation for drug absorption. Enhancment of solubility can
provided sufficient drug amount for absorption [6, 7].
1.1.2 Determination of solubility
Compound aqueous solubility can be seen as a capacity to form hydrogen bonds
with water molecules. Or it can be seen as how easily its constituent atoms are

3

Figure 1-2.

Relationship between Dn, Do and An.

surrounded (form hydrogen bonds) by water molecular network. Solubility is measured
when an excess amount of drug is dissolved in aqueous media, which can be water for
neutral drug or buffer for weak acid or base, at a certain temperature and pressure [4].
Analysis is commonly an HPLC or other specific method. The common definition of the
degree of solubilization is described as in USP:








Very soluble: Less than 1 part solvent needed to dissolve 1 part solute
Freely soluble: From 1 to 10 parts solvent needed to dissolve1 part solute
Soluble: From 10 to 30 parts solvent needed to dissolve 1 part solute
Sparingly soluble: From 30 to 100 parts solvent needed to dissolve 1 part solute
Slightly soluble: From 100 to 1000 parts solvent needed to dissolve 1 part solute
Very slightly soluble: From 1000 to 10,000 parts solvent needed to dissolve 1 part
solute
Practically insoluble: More than 10,000 parts solvent needed to dissolve 1 part
solute

1.1.3 Determination of permeability
After drug dissolution in the GI tract, it is ready for crossing the gut membrane.
The drug mass crossing membrane would subsequently enter the blood. The permeability
indicated how easily and how much of drug crosses membrane in a given time. An In
vitro cell line method and in vivo or in situ intestinal perfusion method are accepted by
regulatory agency for determination of permeability [8]. Both methods need compound
with known permeability as internal standard or reference drug.
The Caco-2 model is widely accepted and applied to measure in vitro
permeability. The cell line Caco-2 is from human colonic cancer cells and used in
transport system research from the 1970s [9]. It can differentiate and form polarized
4

monolayer with tight junction between cells. These properties are similar with that of
intestinal cells. Moreover, Caco-2 cells have several transport systems: including amino
acid, vitamin B, glucose, bile acid, small peptide transporters and P-glycoprotein efflux
system. Figure 1-3 (Modified from Ref. [10]) shows a Caco-2 cell permeability model. A
drug or reference solution is added to the upper compartment, and then incubated for
hours. A sampling point is set to derive a mass transport per time (dm/dt) curve for
permeability calculations. For the Caco-2 permeability calculation, see Equation 1-7.
Peff = (dm/dt) / (A × C0× 60)

(Eq. 1-7)

In this equation, Peff is the effective permeability in cm/sec, m is mass across the
membrane, A is surface area (cm2) for transport, C0 is the slope of best fit line for the
curve dm/dt, C0 is the initial drug concentration (µM). If the Peff of a drug is higher than
2×10-4 cm/s, then complete drug absorption will be considered, otherwise, drug
permeability is low and the absorption is incomplete[11].
Another widely used method is in situ single-pass (closed loop) rat perfusion
model. Similar toCaco-2 cell model, an internal standard or reference compound is also
required. See Figure 1-4, from Ref. [12] for in situ perfusion rat model diagram.
The segment of small intestine (about 6-8 cm) is cut from gut with fully blood
supply. One end is cannulated to allow for drug injection by syringe. The other end is
connected with a tube for sample collection. The remaining drug in the intestine is
collected in a sample vial for concentration measurements by LC-UV or LC-MS. The two
ends of remaining intestine are tied off by a silk suture. The rat moves freely in a
restraining cage during experiment. After experiment, the animals are euthanized. This
model is accepted by the FDA as a tool to determine permeability, regional disposition,

Figure 1-3.

Caco-2 cell permeability model diagram.
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Figure 1-4.

Intestinal perfusion model.

mechanisms of absorption and excretion of drugs, etc [9]. The Permeability calculation
for this model is shown in Equation 1-8.
Peff = [-Qin ln (Cout / Cin)] / 2rL

(Eq. 1-8)

Where Cout and Cin correspond to the drug concentration out of the intestine and
the drug concentration flowed in intestine respectively. While r is the rat intestinal radius
which is set to 0.18cm; L is the length of isolated intestine, commonly 6~8 cm [13]. Q is
the flow rate through the intestine.
Sometimes, for generic drug applications, sponsors provided permeability
determined by Caco-2 model and in the situ single-pass (closed loop) rat perfusion
model.The results from two models can be similar in some cases, but also can be
different. The advantage of the Caco-2 cell model is its cost savings: the cell culture is
cheaper than animal studies and the experiment can be designed for high throughput
compound screening. The disadvantage includes Caco-2 cells that are from a colonic cell
line that is differentiated into small intestinal –like tissue. Actually its tight junction
between cells is more like colonic cells than small intestine cells which can cause a
permeability under-prediction for low absorption drugs [14]. Secondly, it may not
express proper transporters as a true small intestine cells would be expected to.
As a result of disadvantages in Caco-2 model, the more accurate in situ rat
perfusion model is often introduced for permeability determinations. Thus, for biowaiver
purpose, sponsors may provide animal permeability result as supplement if the Caco-2
model under-predicts permeability [9].
1.1.4 Determination of dissolution
The priority condition for oral drug absorption is the dissolution of drug at the site
of absorption. The Noynes-Whitney equation (Equation 1-9) described the variables that
can affect drug dissolution:
6

dm/dt = DS (Cs – Ct)/ Vh

(Eq. 1-9)

In the equation, dm/dt is the dissolution rate, which means the change in the
amount of drug dissolved (m) per unit time (t); D is the diffusion coefficient which
related to temperature, solute radius and viscosity of diffusion medium. S is the surface
area; h is the thickness of the diffusion film adjacent to the dissolving surface; Cs is the
saturation solubility of the drug molecule; Ct is the concentration of the dissolved solute;
and V is the volume of the dissolution medium. From the equation we can see, increasing
surface area as particle size decreases, or increasing saturation solubility can both
increase dissolution rate [15]. If dissolution of drug is faster than its gastric emptying,
(this point is true for BCS class I drugs), basically, dissolution won’t influence the
bioavailability of drug. For this type of drugs, they can express the similar bioavailability
but their dissolution can be different. In this case, the gastric emptying rate will be the
limiting factor for drug bioavailability (BA). For BCS class I drug, in vivo in vitro
correlation (IVIVC) could be constructed [16].
For BCS class II drugs with low solubility and high permeability, dissolution rate
and extent can both be the rate-limiting factor to drug absorption. Dissolution rate can be
increased by decreasing particle size; where extent of dissolution increase depends on
solubility enhancement which can be introduced by many new techniques besides adding
surfactant in formulation.




Class I: High Solubility – High Permeability
Class II: Low Solubility – High Permeability
Class III: High Solubility – Low Permeability

For BCS class III drugs with low solubility and high permeability, they are easily
soluble as class I drug; it is gastric emptying rate rather than dissolution rate that affect
more on BA. The low permeability is the limiting factor for their oral absorption. If the
drug absorption occurs as linear process, increasing dose is a way to increase
bioavailability. Or if P-glycoprotein pumped the drug out of membrane, then the Pglycoprotein inhibitor may be added in formulation to inhibit its efflux function [3].
Drugs with low solubility and low permeability are categorized to BCS class IV.
These compounds have poor oral bioavailability and are not easy to develop oral dosage
form. Generally, non-oral dosage form will be considered for BCS class IV compound.
However, there are still few oral BCS class IV drugs on market: hydrochlorothiazide,
taxol, and furosemide.
For oral dosage forms after administration, the drug is passed into stomach,
disintegrates here, then drug dissolves to allow absorption. Simulated gastric fluid (SGF)
is commonly used as a dissolution media. Since the small intestine is the major area for
most drug absorption, simulated intestine fluid (SIF) is another commonly used
dissolution media. When developing dissolution method for BCS class I or class III
drugs, a volume of 900 ml can provide sink condition for those drugs dissolution;
surfactant maybe added in SGF or SIF to make sink condition for BCS class II or class

7

IV drugs. Besides the aforementioned dissolution media, other bio-relevant media are
prepared for mimic fast state gastric condition, fed state gastric condition, fast state
intestine condition and fed state intestine condition. In the dissolution media, surfactants
and enzymes are often also selected as needed [17].
Basket (USP apparatus I) or paddle (USP Apparatus II) dissolution is the most
commonly used methods for oral dosage form. The volume of media is generally set to
900 ml. For high soluble BCS class I and III compounds, the duration time should be
shorter than that of BCS class II or IV. For IVIVC purpose, the dissolution criteria is set
by FDA as no less than 85% drug substance is dissolved in three different dissolution
media (SGF with pH1.2 without enzyme, pH 4.5 buffer and SIF or pH6.8 buffer without
enzyme); for each formulation, 12 dosage units are evaluated. Sampling points should be
enough to derive the dissolution curve for comparison [18]. The variance of initial point
on dissolution curve (like 10min point) should be less than 20%, the following points
should be within 10% variance. The similarity factor (f2) is required to compare the
dissolution profiles. See Equation 1-10 for f2 value calculation.
f2=50∙ log 1

]-0.5 100

∑

(Eq. 1-10)

Where n is the number of time points, Rt is the mean cumulative percent
dissolved of a reference drug at time t, Tt is the mean cumulative percent dissolved of a
test drug product at time t. If no less than 85% drug dose dissolved within 30min, f2
value comparision is not necessary. If 85% drug amount dissolution is longer than 30min,
then f2 value may be calculated to compare dissolution profiles. Two dissolution profiles
would be considered similar if f2 ≥ 50 and the difference of two dissolution profile is less
than 10% [19].
1.2 Formulation Strategies for Poorly Water Soluble Drug Development
Currently, BCS is widely accepted as a must tool in new drug or generic drug
development. In the early stage of drug development, solubility and permeability of lead
compounds are measured to decide which category the drug belongs to. Then a
formulation strategy has been previously used successfully might be considered for this
compound. For class I compounds, they are easily soluble and have good absorption,
formulation for these compounds is more likely to be a stability issue than a dissolution
problem. For class II compounds, a formulation strategy is critical to improve dissolution
rate if the limiting-step of absorption is dissolution rate or improve solubility if the drug is
solubility-limiting oral absorption. Micronization, nanotechnology, cyclodextrin
complexation, lipid based formulation, micellization, microemulsions and solid
dispersion are accepted approaches to handle poorly solubility issues. It is not easy to
develop BCS class III compounds because it is hard to change permeation of drug and
membrane. Some permeation enhancers have been studied for this purpose [20-22]. For
BCS class IV compounds, approaches for improving solubility and permeability are
needed at the same time, plus it is necessary to understand the compound absorption
mechanism and factors affecting bioavailability. Alternative delivery methods, such as
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i.v. or it may be necessary to go back to lead chemical optimization. Nevertheless, several
Class IV drugs do exist. Examples include taxol, cyclosporin A and furosemide. In these
innovative formulation strategies, nanotechnology and lipid based formulations will be
discussed in the following subtopics, as well as cyclodextrin complexation. Solid
dispersion approachs will be discussed in details in Chapter 2.
1.2.1 Nanotechnology in poorly water soluble drug development
Particle size reduction is an effective tool to enhance the dissolution rate of poorly
soluble drugs. It is well known that the micronization can increase in vivo absorption and
bioavailability of poorly water soluble drugs. But micronization works for those drugs
that oral absorption is limited by dissolution rate. The micro-scale particles are not small
enough to increase oral bioavailability of those drugs which oral absorption is limited by
solubility, such as high dose BCS class II drugs. But in the case of reducing particle size
to nano-scale, the oral BA of aforementioned two type poorly soluble drugs can both be
enhanced [23]. Some nanosuspensions on market or in clinical trials are listed in below.
Nanosuspensions we will discuss here is a colloidal dispersion of pure drug
particles in water with other necessary ingredients. The particle size for nanosuspension
is generally smaller than 300 nm for Brownian motion to keep system stable. Individual
particle in a nanosuspension cannot be seen by the naked eye. The drug particle in
nanosuspersion is in a preferred crystalline form with sufficiently small size. Usually, the
preferred API for this formulation is those insoluble drugs with solubility less than 0.1
mg/ml. If the solubility is higher than 0.1 mg/ml, other strategies including co-solvent,
surfactant, emulsion, etc. might be utilized [24].
1.2.1.1 Formulation rationale and ingredient function
The constituents of a typical nanosuspension include drug (API), stabilizers,
surfactants and water. Basically, the nanosuspension is a thermodynamically stable
system with high energy. The preparation process is a surface area increase process
which will induce free energy increase. But adding surface-active agents can compromise
the surface change effect by decreasing interfacial tension, thus keep or decrease free
energy. This basic principle can be shown Equation 1-11, where G is change of free
G = s/l •A

(Eq. 1-11),

energy, s/l is the interfacial tension between solid (particle) and liquid (water), A is the
change of surface area. Generally, two type surface-active agents: ionic surfactant and
non-ionic surfactant are used in nanosuspensions [25]. Function of polymer and
surfactant in preparation and stabilization of nanoparticles is shown in Figure 1-5,
modified from ref. [25].
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Figure 1-5.

Function of polymer and surfactant in nanoparticles.

In Figure 1-5, for the case of circle a, hydrophobic crystal surface directly
contacting water molecules leads to crystal agglomeration. For the case of circle b,
polymer and surfactant synergy stabilized crystal surface, the stabilizers not only reduced
contact opportunities between water and crystal particles, but also decreased interfacial
tension by attraction between water and surfactant. In a nanosuspension, two close
nanoparticles tend to agglomerate because of Van Der Waals attractive forces or
hydrophobic attraction, but with a polymer and surfactant in the system, the trend can be
reduced by steric repulsion or electrostatic repulsion from exicipient.
This point can also be interpreted as polymer molecules inserted into API
particles thus increasing the distance of two hydrophobic particles and decreasing their
hydrophobic attraction. When adding ionic surfactants, these molecules attached at the
interface of water and nanoparticles to not only reduce the interfacial tension (s/l), but
also incur static repulsion to prevent crystal growth and particle agglomeration.
Commonly used polymer and surfactant include cellulose derivatives; poloxamer,
polysorbates, transcutol, etc. are shown in Figure 1-6. Selection of exicipients will be
according to the properties of API [26].
1.2.1.2 Nanosuspension preparation methods
The first successful scale-up nanosuspension manufacture technique is owned by
Elan Drug Delivery. It is media mill. The mechanical diagram is shown in Figure 1-7.
The API particles (after premilling by ball mill or micronized API) are mixed
together with selected surfactants and polymer in water, then place the suspension in the
chamber which is charged by milling media, a drive shaft attached to rotating disk to
make it rotate at a very high shear rate. A cooling system is included to make the whole
process under controlled temperature. In process, particle size is determined by stress
intensity and the number of contact points between API crystal and media grinding
10

Figure 1-6.

Relation in nanoparticles, polymer, surfactant and water molecules.

Figure 1-7.

Schematic representation of the media milling process.
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beads. After milling 30 ~ 60 min, the particle size can be reduced to 200 nm with narrow
distribution. The variance among batches is very small ( 2%) [23].
High pressure homogenization is another technique that applied to prepare
nanosuspension from lab to manufacture scale. The schematic diagram of this piston-gap
homogenizer is shown in Figure 1-8. For this method, pre-suspension is necessary before
preparing nanosuspension. The pre-suspension, usually a micronized, particle size which
can be smaller than 5 µm, placed in the chamber to pass through a narrow channel
(homogenization gap), the flow velocity is increased tremendously under high pressure
(1400 bar). According to Bernoulli principle, simultaneously static pressure of presuspension fluid decreased which reduced the boiling point of water, then water start to
evaporate to form bubble in the boiling area. At the same time, the pre-suspension goes
through the channel (e.g. 25 µm), then water bubble implodes when fluid leaves channel
due to the pressure change (cavitations effect). The energy produced from cavitations’
cracked the fluid into nanoparticles. In this method, suspension needs to be micronized in
case big particles occlude the narrow channel. Homogenization pressure and numbers of
homogenization cycles are keys for final product quality [23, 27, 28].
Other methods include crystal precipitation, emulsion or microemulsion as
templates to prepare nanosuspensions. The drug will be first dissolved in a solvent or cosolvent, then form nuclei at slow speed by adjusting temperature, then optimizing
temperature for crystallization at a fast speed to keep the size of crystals in nano-scale.
During this crystal precipitation process, the control of temperature is the key. When
preparing nanoparticles from emulsions or microemulsions, the first step is to form a
stable emulsion, then agitate water phase under high stirring speed, the solvent
evaporated, solid particles obtained. Surfactants are necessary in the process [28].

Figure 1-8.

Schematic diagram of homogenization process.
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1.2.1.3 Characterization and key factors affecting product quality
Particle size distribution, stability and bioavailability are three critical factors
affecting the quality and efficiency of nano-suspensions. Laser light diffraction is used to
analyze the drug substance in aqueous nano-suspensions. In data calculation, Fraunhofer
and Mie therories are employed. The former one is the default for particle size
calculation. In the USP, if particle size is smaller than 25um, Mie theory can also be
applied. If inconsistent results occurred, other techniques such as scanning electronic
microscopy (SEM) and Mie theory will be applied. XRPD is also used to characterize the
solid form or polymorph. Stability is tested under the accelerated condition to see if
agglomeration occurred, shipping conditions are also evaluated, too. Bioavailability is
determined by conducting bioavailability and pharmacokenetic studies; Cmax, Tmax and
AUC are compared to reference formulations [29, 30].
1.2.1.4 Commercial products and promising drug product status
Currently commercial products include tablet, suspension and capsule. Rapamune
is an immune-suppressant tablet based on Elan nano technique which is manufactured by
Wyeth. Merck also has one nanoparticle product: Emend which is anti-emetic drug in
capsule form applying Elan nano technique too. In addition to aforementioned drugs,
there are several drugs on every stage of clinical trial [31].
1.2.2 Self-emusifying drug delivery system
Several type of drug formulation system can be categorized as lipid based drug
delivery systems. These formulation approaches also target to deliver poorly water
soluble drugs. Self-emusifying drug delivery system (SEDDS) is one of these
approaches. Excipients including oil, co-solvent and surfactant are mostly often
considered in this system. The mixture of oils, surfactant, and often drug co-solvents are
supposed to be isotropic. When the whole system contacts with water in vitro or in vivo,
the oil in water emulsion will be formed and drug is released [32].
1.2.2.1 Basic principle and excipient function
The exactly mechanism of how the system works is still a remaining work for
discover. But commonly reorganization is the relationship among liquid crystal
formation, oil-water phase inversion temperature, the increased water solubility by lipid
formulation that affects the self-emusifying efficiency. The equilibrium phase diagram is
the priority part for the SEDDS development. The oil is the most important ingredient in
the SEDDS which is used as drug solvent and oil phase, sometimes, a co-surfactant will
be selected to work together with oil to dissolve more drugs. Both long and medium
chain triglyceride oils are candidates. In SEDDS, food oils are not frequently used due to
the low efficiency in dissolving API and long term stability issue [33].
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The most commonly used surfactants in SEDDS are non-ionic surfactants which
have high hydrophilic-lipophilic balance (HLB). Ethoxylated polyglycolyzed glycerides
and polyoxyethylene 20 oleate (Tween 80) are two types of widely used surfactants. The
usual amount of surfactant in SEDDS is about 25~60%. The high usage amount of
surfactants may induce a toxicity problem which is a major concern in surfactant
selection. Even with Tween 80, it may cause GI irritation when used in long chronic
application. Considering the toxicity issue; the choice of surfactant will be generally
limited to the aforementioned two types. The type and amount of surfactant are two
critical parameters to develop a good formulation. In SEDDS, surfactant is incorporated
in the interface of oil and water, to help form micelles or fine-emulsion. With surfactant,
the interfacial tension between water and oil can reach ultra-low values which will
benefit drug stabilization in oil and fast dispersing when met with large amount water or
fluid, such as in the GI tract [34].
The co-solvent is also a critical ingredient in SEDDS. Propylene glycol (PG), and
polyethylene glycol (PEG) are two poplar so-solvents. It helps to dissolve API and
quickly disperse SEDDS to form fine oil in water emulsion in drug dissolution and
absorption.
1.2.2.2 Phase diagram and characterization tools
A phase diagram is the first step to develop a SEDDS. Usually the constituents of
oil, co-solvent, surfactant and water without drug will be first tested at room and
physiogical temperature to construct a phase diagram. An initial ratio between oil, cosolvent and surfactant will be assigned empirically as a starting point; the proper ratio
among of oil, cosolvent and surfactant will be decided from the first phase diagram. Then
the optimized ratio between oil and cosolvent is set as one component to construct second
three phase diagram or pseudo three-phase diagram. A typical three-phase diagram is
shown in Figure 1-9. A series of screening experiments is necessary to construct it. The
triangle line is single phase line; the line inside is two components equilibrium line, two
components are miscible in this line; the gray area inside triangle is the miscible area of
three components which is what we need. Basically, the mix ratios of components in the
gray area can be selected to further incorporate drug. According to drug dose and loading
amount, the ratio among oil, co-solvent and surfactants would be adjusted [32, 35].
Upon dissolution, when SEDDS meets water or fluid in GI tract, it should
disperse quickly and form fine oil in water emulsion. The co-solvent in the system assists
the quick dispersion and large amount of surfactant is quickly distributed at the interface
between oil and water to decrease the interfacial tension. Drug is kept in oil and ready for
absorption [33, 36].
Upon dissolution or when the drug entered GI fluid, precipitation problems
happen occasionally this is the intrinsic property of SEDDS. In that case, phase
equilibrium is broken and drug can precipitate out. Phase break can be induced by
temperature change, such as temperature changed from room to physiological condition,
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Figure 1-9.

Scheme of typical three-phase diagram under isothermal condition.

cloud point reached; or induced by inability of the system to contain the drug under the in
vivo conditions.
1.2.2.3 Commercial products
Several marketed products are applied SEDDS in their formulation and clinical
practice shown benefit over side effect of high amount of surfactant. These drugs are
summarized in Table 1-1, including major ingredients of each formulation [37, 38].
1.2.3 Cyclodextrin application in drug delivery
Cyclodextrin are cyclic oligosaccharides of glucose. Usually when one molecular
cyclodextrin contains 6, 7 or 8 glucose molecules, these oligomers will be referred to as
α, β or  cyclodextrin. The cylinder shape molecules have amphiphilic properties that can
form water soluble complex with small molecules and specific portion of large
molecules. The shape and complex of cyclodextrin diagrams are shown in Figure 1-10.
The outside of cylinder is hydrophilic which incur the water solubility to
cyclodextrin, the inside cavity is hydrophobic which form complex with poorly water
soluble drug, thus increase the apparent solubility of drug, then further increase the
bioavailability. It can also benefit the drug stability, prevent degradation of compound
[39, 40].
The first cyclodextrin was discovered in 1891 and the first patent of cyclodextrin
in drug formulation was issued to Freudenberg et al. in 1953. After that, the research on
cyclodextrin became hot area for some years. During these years’ study, the chemical
properties including determination method, molecular structure characterization, drug
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Table 1-1. Summary of commercial SEDDS drug products.
Trade name Generic name Dosage form
Sandimmune® Cyclosporine A

Soft gelatin
capsule

Surfactant

Solvent

Linoleoyl
macrogolglycerides Alcohol
(polyoxylglycerides)

Oil

Company

Approval
date

Corn oil

Novartis

2-Mar-90

PG/Corn oil monoNeoral *
Ethanol di-triglycerides/ αNovartis
14-Jul-95
tocopherol
Soft gelatin
Cremophor EL
Ethanol
Abbott
Norvir®
ritonavir
Oleic acid 75%
10-Feb-10
capsule
(HLB 12~14 ) ~13% 12%
laboratories
Medium chain
Soft gelatin
mono- and diHoffmann‐La
®
Fortovase
Saquinavir
NA
Povidone
24-Dec-03
capsule
glycerides, DL-αRoche lnc.
tocopherol
Soft gelatin
PG (phosphatidyl
Agenerase®
Amprenavir
TPGS (HLB ~13) PEG 400
Glaxosmithkline 5-Feb-02
capsule
glycerol )
* Neoral® is not bioequvelent with Sandimmune®, it has high bioavailability than Sandimmune®.
®

Soft gelatin
Cyclosporine A
capsule

Cremophor RH 40
(HLB 14~16)
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Figure 1-10. Schematic diagram of cyclodextrin-drug complex.
solubilization mechanism, complex form capacity are thoroughly disclosed. Besides
chemical structure and function, biology, pharmacokenetics, pharmacodynamics and
toxicity in human and animal are also studied. These researches found renal toxicity of
cyclodextrin when administered i.v. Oral applications do not have renal toxicity since
enzymes excreted from pancreas and stomach can degrade cyclodextrin. But fortunately,
chemical modifications done to original cyclodextrins reduced toxicity and made it safe
to be used as a solubilizer for i.v. Modified cyclodextrin not only improved the safety but
also the aqueous solubility. The solubility of α, β or  cyclodextrin in water at ambient
temperature is 13%, 2% and 26% w/w respectively, whereas modified cyclodextrins have
increased solubility which can reach to 60% w/w or even more. Currently, application of
cyclodextrin have become a common solution for formulators to solve solubility problem
of poorly water soluble drugs in various administration routes, including oral,
ophthalmic, i.m., i.p., etc. Two modified β-cyclodextrins: hydroxypropyl-β-CD (HPβCD;
Figure 1-11) and sulphobutyl ether derivatives of β-CD (SBEβCD; Figure 1-11) are
widely accepted as i.v. excipient by regulatory agency in many countries [41].
Cyclodextrin are successfully used as drug solubilizers and have made
commercialization of many drugs possible. Table 1-2 summarized marketed drugs with
cyclodextrins [39]. Cyclodextrins do have some disadvantages, such as low drug loading
which limits its application to lower dose potent drugs and a relatively high price.
1.3 Summary
Based on BCS classification, drugss are divided into four categories. For class II
and class IV, the drug solubilization is a critical issue for product development. The
selection of formulation strategies can be various, from simple to complicated, from low
to high price. The screening sequence can follow: co-solvent, alcohol, lipids; or new
techniques, such as SEDDS, nanosuspension, solid dispersion. But for those new
techniques, each has its own advantage and disadvantages. The benefit-risk or benefiteconomy would be evaluated for a decision. The solid dispersion technique will be
discussed in detail in Chapter 2.
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Figure 1-11. Graphic diagram of HP-β-CD and SBE-β-CD.
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Table 1-2. Summary of drug products using cyclodextrin.
Drug

Administration
route

Alprostadil (PGE1)

Intravenous

Trade name

Prostavastin,
Europe, Japan, United
Caverject, Edex
States
Pansporin T
Japan
Opalmon, Prorenal
Japan

Cefotiam hexetil HCl
Oral
Limaprost
Oral
β-Cyclodextrin (βCD)
Benexate HCl
Oral
Ulgut, Lonmiel
Cephalosporin
Oral
Meiact
Cetirzine
Oral
Cetrizin
Chlordiazepoxide
Oral
Transillium
Dexamethasone
Dermal
Glymesason
Dextromethorphan
Oral
Rynathisol
Diphenhydramin and
Oral
Stada-Travel
chlortheophyllin
Ethinylestradiol and
Oral
Yaz
drospirenone
Iodine
Topical
Mena-Gargle
Meloxicam
Oral and Rectal
Mobitil
Nicotine
Sublingual
Nicorette
Nimesulide
Oral
Nimedex, Mesulid
Nitroglycerin
Sublingual
Nitropen
Omeprazole
Oral
Omebeta
Dinoprostone (PGE2)
Sublingual
Prostarmon E
Piroxicam
Oral
Brexin
Tiaprofenic acid
Oral
Surgamyl
Cisapride
Rectal
Propulsid
Hydrocortisone
Buccal
Dexocort
Indomethacin
Eye drops
Indocid
Itraconazole
Oral, intravenous
Sporanox
Mitomycin
Intravenous
Mitozytrex
Randomly methylated β-CD
17β-Oestradiol
Nasal spray
Aerodiol
Chloramphenicol
Eye drops
Clorocil
Sulphobutylether β-CD
Aripiprazole
Intramuscular
Abilify
Maropitant
Intravenous
Cerenia
Voriconazole
Intravenous
Vfend
Ziprasidone maleate
Intramuscular
Geodon, Zeldox
Diclofenac sodium
Eye drops
Voltaren
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Market

Japan
Japan
Germany
Argentina
Japan
Europe
Europe
Europe, United States
Japan
Egypt
Europe
Europe
Japan
Europe
Japan
Europe
Europe
Europe
Europe
Europe
Europe, United States
United States
Europe
Europe
United States
United States
Europe, United States
Europe, United States
Europe

CHAPTER 2.

SOLID DISPERSION REVIEW

This chapter is intended to combine recent literature on solid dispersion
technology for solubility enhancement with various preparation methods, evaluation
parameters and commonly used polymer carriers. Solubility behavior is one of the most
challenging aspects for drug commercialization or one of the main reasons for a drug that
does not reach to its full potential. Currently, nearly 60% of new chemical entities
possess solubility problems, whereas practically no drug products with less than 10 μg/ml
solubility in 70’s or 80’s. Various techniques have been applied to enhance drug
solubility such as the use of co-solvents, particle size reduction, lipid based drug delivery
systems, nanosuspensions, use of surfactants, salt formation, cyclodextrin complexes and
solid dispersions etc. In this chapter, several drug products using solid dispersion
techniques are also reviewed.
2.1 Definition and History of Solid Dispersion
Chiou and Riegelman have defined solid dispersions in 1971 as “a dispersion of
one or more active ingredients in an inert carrier at the solid state, prepared by the
melting, the solvent or the melting solvent method” [42]. A solid dispersion consists of at
least two components: hydrophilic matrix and hydrophobic drug. The matrix can be
either crystalline or amorphous in structure. In 1971, solid dispersion was summarized as
the following 6 types [42]: group 1, simple eutectic mixtures; group 2, solid solutions: a
solid solute dissolved in a solid solvent, two components crystallize together in a
homogeneous one-phase or more than one phase system; group 3, glass solutions and
glass suspensions, the solute dissolved or dispersed in the glassy solvent; group 4,
amorphous drug was dispersed in crystalline carrier; group 5, complex formation between
the drug and the carrier; group 6, any combination among groups 1-5. From the point of
physical state of drug in solid dispersion, drug was crystalline in simple eutectic mixture;
in glass solutions, the drug and the carrier were both amorphous form. However, over the
years, new formulation techniques for poorly soluble drugs made the line of classification
less clear. The nanosuspension can be absorbed in solid absorbents to make nanoparticles
dispersed and stabilized in solid matrices. Cocrystals can be classified into solid solutions
and in lipid formulations or self-emulsifying drug delivery systems, drug can also be
dispersed or dissolved in solid matrices [43]. The schematic diagram of the classification
system and the new techniques overlap with it is shown in Figure 2-1. Nowadays, most
solid dispersions are glass solutions or glass suspensions in which a hydrophilic polymer
with high glass transition temperature was selected as carrier material and the drug can be
molecularly dispersed or precipitated as amorphous form in the carrier [44]. The
crystallization process can be prevented by the viscous medium.
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Figure 2-1.

Scheme of solid dispersion classification system and new techniques.

2.2 Dissolution Rate or Solubility Enhancement Mechanism from Solid Dispersion
According to the preparation method, a number of strategies can be adapted to
increase solubilization of poor water soluble drug and its dissolution rate in dosage form.
2.2.1 Enhanced wettability
A hydrophilic material as solid dispersion carrier can be utilized drug dissolution
enhancement. The fast hydration of the surface of one phase solid dispersion system
allows water to easily contact with the drug and the drug quickly release from dosage
form [45]. Carriers with surface activity, such as surfactants can significant decrease the
interfacial tension between dissolution medium and surface of dosage form, which also
results in enhanced dissolution rate. The drug loading or the ratio between drug and
carrier has a strong effect in the wettability of solid dispersions. Generally, a low drug
loading or a high amount of polymer used in solid dispersion demonstrated better
wettability [46, 47].
2.2.2 Particle size reduction
In a melt-quench method, drug and carrier are melted together and then quenched
to form hard clump as one phase system. In the solvent evaporation method, drug and
carrier are dissolved in common solvent and then evaporated rapidly. Solid dispersion
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clumps or powders left for further processing. In either of the two preparation methods,
the drug is dispersed in the carrier at a molecular level. No distinguished drug particles
can be observed in the solid dispersion. When drug releases from solid dispersion in
aqueous media, the increased specific surface area of drug can be help to form colloid
solution resulting in higher dissolution rate [43].
2.2.3 Reduced aggregation and agglomeration
Particle size reduction increases surface area of particles, thus it can improve the
drug dissolution rate. However, for the pure fine particles (0.1 µm), aggregation and
agglomeration may commonly occur. Since the specific area of fine particles increases
tremendously, the Van der waal’s attraction and electrostatic charge among particles
increases to cause particles to agglomerate and aggregate. When those pure fine particles
meet with dissolution media, their poor water wettability properties made them dissolve
slower than that of more coarse particles. In solid dispersions, this problem is overcome.
The hydrophobic drug particle is surrounded by a matrix which prevented the
hydrophobic attraction efficiently thus reduced the agglomeration or aggregation of
particles [42]. The dissolution rate of a solid dispersion has been enhanced by the aid of
solid dispersion hydrophilic carrier material. Various hydrophilic polymers form solid
dispersion with poor water soluble compound demonstrated this point [48, 49].
2.2.4 Amorphous state of drug
Compared to its crystalline counterpart, the amorphous form of drug does not
have a defined structure, and lower intramolecular or intermolecular attraction. Thus no
energy is required to break crystal lattice in the amorphous state during dissolution. These
properties allow the system to be easily hydrated and dissolved in water. The higher
solubility promotes a fast dissolution rate [50, 51]. The maintenance of supersaturation
state of drug in dissolution media or GI tract is the major reason to promote a fast
dissolution rate to achieve better bioavailability. The amount of polymer used in solid
dispersion affects the drug supersaturation state significantly, the more polymer used, the
higher degree of supersaturation [52]. Thus, using the advantage of amorphous form,
keeping it stable and preventing its recrystallization has been a critical issue in
formulation development. Selection of the carrier polymer, its ratio to drug, as well as
preparation method play important role in a successful solid dispersion dosage form.
More and more research demonstrated that the major mechanism of solid dispersion was
the amorphous state of drug.
2.3 Preparation Methods
Traditionally, three basic methods have been used to prepare solid dispersion
which is melting or fusion, solvent evaporation, and melting combined solvent
evaporation method [42]. From the first solid dispersion formulation: sulfathiazole-urea
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solid dispersion published by Sekiguchi [43] in 1960s’ till now, the research of solid
dispersion is constantly expanding. The concentrated research has encouraged the
emergence of many novel methods to prepare solid dispersion in lab scale, pilot and
scale-up to manufacture size. The hot melt extrusion approach and spray drying
technique have made solid dispersion dosage form commercialization possible. The two
techniques have been the major processes in solid dispersion drug product manufacture.
2.3.1 Hot melt extrusion
The principle is co-melting or co-fusion: drug and carrier were heated together
until melting to a clear liquid, and then quenched the melt to get solid dispersion. This
method was first described by Sekiguchi and Ovi [53]. They prepared solid dispersion by
melting the sulfathiazole-urea mixture, cooling the melt in an ice bath, and then the hard
cooled melt was pulverized into powder. Nowadays, many solid dispersion experiments
conducted in laboratories still use this method. Hot melt extrusion is an industrial
applicable variation of the melting or fusion method. A specific machine has been
designed and applied for this purpose. Hot melt extrusion equipment is commercially
available from laboratory scale or manual operation to manufacturing scale or automatic
operation. The procedures described below for the preparation of solid dispersion using
hot melt extrusion. A powder blend of drug and polymer carrier is introduced into a
heated barrel via hopper. A single-screw or twin-screw is installed in the barrel where the
powder blend is intensively mixed, heated and moved to a shaping part which shapes the
soft materials as granules, small cylinders, or films via various dies. Then the outcome of
hot-melt extrusion will be further processed into a capsule or tablet. The simple flow
chart of this procedure is shown in Figure 2-2. The feeding hopper, barrel with screw
inside, die system and engine are the basic components consist of hot melt extrusion. A
schematic diagram of hot melt extrusion is shown in Figure 2-3, modified according to
[54].
In the heating barrel, a single screw or twin screw is installed to move the mixing
melt. Compared to the single screw extruder, the twin screw extruder has some
advantages: material can be fed easier and quicker; it has high kneading potential and
material dispensing capacity; it is more efficient heating and mixing make the chance of
material overheating less and shortens the operation time. Two rotation modes are
designed for twin screw extruder. The two crews can co-rotate or counter-rotate. The
commonly used rotate mode is co-rotating which can operate under high screw speed and
more flexible design in screws. For counter-rotating extruder, a low screw speed is
preferred since high screw speed will introduce a high pressure and high shear force

Figure 2-2.

Schematic flow chart of hot melt extrusion process.
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Figure 2-3.

Schematic diagram of components of a single screw extrusion.

between screws which has high potential to damage the parts. High speed can also entrap
air which cause defect in final extrudates [55]. However, the low cost and mechanically
simplicity of the single screw extruder make it still one of the selections for users.
Several parameters in the hot melt extrusion procedure need to be considered and
optimized for a specific experimental process. Those parameters include the barrel
temperature, material feeding rate and screw speed. The melt pressure is decided by other
parameters. The barrel temperature is decided by the melting point of the drug and the
glass transition temperature of polymer and it is accurately controlled by instrument in a
range of 30°C to 250°C.
Besides the application in pharmaceutical industry, hot-melt extrusion is widely
used in plastic and rubber industry to manufacture pipes, hosed insulated wires and
cables, etc. In pet food industry, extrusion has been commonly used to produce palletized
feeds for animals [54]. It has been used in food industry for pasta or ground meat
production since 1930’s [56].
Solid dispersion prepared using hot-melt extrusion method is used not only in oral
dosage form development to help in solubilization of poor water soluble drugs but also
used in transdermal delivery system, implants and sustained release drug delivery system.
Several marketed solid dispersion drug products are listed in Table 2-1.
Besides marketed drug products, many research papers about solid dispersion
study using hot melt extrusion technique have been published. The model drugs selected
in these papers are generally BCS class II or IV compounds. Only the latest literature
will be reviewed below since many papers have been covered in former review articles
[42, 43, 46, 50].
Andrews et al investigated solid dispersion of bicalutamide and PVP prepared by
hot melt extrusion technology. A single Tg in DSC, no sharp peak diffraction pattern of
PXRD and enhanced dissolution rate indicated amorphous bicalutamide and PVP solid
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Table 2-1.

Examples of commercial solid dispersions.
Number

Drug
product

FDA
approval

Technology

Drug

Carrier

1

Gris-PEG

1975

Melt process

Griseofulvin

PEG 6000

2
3

Cesamet
Prograf

1985
1994

Nabilone
Tacrolimus

PVP
HPMC

Itraconazole

HPMC

2004

Melt extrusion
Unkown
Spray dry onto
substrate
Unkown

4

Sporanox

J&J

1996

5

Certican

Novartis

HPMC

Abbott

2005

Melt-extrusion

Everolimus
Lopinavir,
ritonavir

6

Kaletra

7

Isoptin SR-E

Abbott

2005

Hot melt extrusion

Verapamil

8
9
10

Intelence
Nivadil
Incivek

Tibotec
Fujisawa
Vertex

2009
Not yet
2011

Spray drying
Unkown
Spray drying

Etravirin
Nivaldipine
Telaprevir

Company
Pedinol
harm Inc.
Eli Lilly
Fujisawa
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PVPVA
HPC/HPM
C
HPMC
HPMC
HPMCAS

dispersion formed. Moreover, stability test has been done at 20 degrees C, 40% RH and
20 degrees C, 65% RH for 12 months, no drug crystallized was observed at 40% RH,
whereas drug crystallized at higher humidity (65% RH). However, drug recrystallization
after storage did not change the dissolution profile of the solid dispersion [57]. Two
methods: hot melt extrusion and cogrinding have been applied to prepare ginsenosides
solid dispersion. In the dissolution test, the solid dispersion prepared by hot melt method
is better than that of solid dispersion prepared by co-grinding method; however, cogrinding method showed better bioavailability than that of hot melt method [58].
Feng J et al investigated the hot melt solid dispersion of bifendate with three
polymers: Plasdone® S-630, Eudragit® EPO and Kollidon® VA 64. DSC and XRPD
indicated that the drug was in amorphous form and dispersed molecularly in the three
solid dispersions. The drug release from solid dispersions was in the order of bifendateKollidon® VA 64 > bifendate-Plasdone® S-630 > bifendate-Eudragit® EPO, while the
relative bioavailability tested in beagle dog was in the order of bifendate-Kollidon® VA
64 > bifendate-Eudragit® EPO > bifendate-Plasdone® S-630. The relative bioavailability
of bifendate-Plasdone® S-630 solid dispersion was lower than that of commercial pills
[59].
Jijun F et al using hot-melt extrusion prepared a solid dispersion of nimodipine
and two polymer mixture: Eudragit EPO and Kollidon VA64. The dissolution result
showed fast drug release from solid dispersion. PXRD and DSC results showed that drug
was in amorphous form in solid dispersion. The accelerated stability (40 degrees C, RH
75%) of solid dispersion tablet was examined for 2 months. Drug dissolution rate was
slightly decreased after 2 month storage even though no crystalline was observed by
PXRD [60].
Another BCS class II drug: celecoxib has been selected as model drug to prepare
solid dispersion using hot-melt extrusion with PVP and Eudragit 4155F. Drug
concentration in dissolution media was significantly higher than its equilibrium
solubility. But the mechanism for this phenomenon was different for the two solid
dispersions. For celecoxib-PVP solid dispersion, the supersaturation state and amorphous
form of drug can be kept in dissolution media by PVP; while for celecoxib-Eudragit
4155F solid dispersion, the polymer also acted as solubilizer that increased the
equilibrium solubility of drug [52].
Two polymers Eudragit E100 and PVP-VA have been selected to prepare solid
dispersion using hot-melt extrusion for fenofibrate which is a BCS class II drug. DSC and
X-ray diffraction showed that the compound was in amorphous form in the two solid
dispersions. The results of drug release in 0.1M HCl and water showed that Eudragit
E100 was better than PVPVA in accelerating drug release. The relative bioavailability of
fenofibrate-Eudragit E100 1:4 (w/w) solid dispersion was 177.1% compared to
micronized Lipanthyl capsule when tested in beagle dog [61].
Solid dispersion of nimodipine with HPMC, PVPVA and Eudragit EPO has been
prepared using hot-melt extrusion. The dissolution results indicated that three polymers
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are suitable carriers to enhance the in vitro dissolution rate of nimodipine in pH 4.5
medium. XRPD and DSC data showed that drug was in amorphous form in hot-melt
extrudates. Nimodipine was miscible with HPMC when drug loading was 10% and phase
separation existed when drug loading was increased to 30% and 50%. The weakening and
shift of the N-H stretching vibration of the secondary amine groups of nimodipine as
determined by FT-IR showed hydrogen bonding between the drug and polymers in the
solid dispersion [62]. The bioavailability study was conducted of the three solid
dispersions in beagle dogs. The HPMC and PVP/VA dispersions exhibited much lower
bioavailability compared to that of Eudragit EPO solid dispersion [63].
Hot-melt extrusion has attracted considerable interest within the pharmaceutical
industry. However, how to identify the nature of the drug dispersion within the polymer
remains a challenge. The following summary of three articles simply described the major
techniques using for solid dispersion characterization.
Sheng Qi et al developed a combined thermal, imaging and spectroscopic
approach for the identification and characterization of the drug and polymer structure.
DSC run at various scan rates, MDSC, microthermal analysis (mu-TA) and ATR-FTIR
were used to characterize the solid dispersions prepared by hot-melt extrusion containing
10% and 20% paracetamol in Eudragit E. Dispersion of the drug in the polymer on a
molecular basis was indicated by observed single Tg. However, DSC and ATR-FTIR also
indicated that the drug was present in both amorphous and crystalline forms
simultaneously. The ATR-FTIR also tested that the crystalline of drug was major in the
center of extrudate. This study indicated that a single technique may not provide enough
required information for fully understanding the complex system [64].
The physical and viscoelastic properties of the hot-melt extrusion prepared solid
dispersions: indomethacin (INM) with Eudragit EPO (EPO), PVP-VA, PVPK30, and
poloxamer 188 (P188) have been investigated by Chokshi RJ et al., A single T(g) was
observed from the thermal analysis studies indicating good miscibility of drug and
polymer for INM/EPO, INM/PVPVA, and INM/PVPK30 systems. In the case of
INM/P188 solid dispersion, two melting endotherms were observed indicating partial
miscibility of drug in polymer. Zero rate viscosity (eta(o)) and activation energy (E(a))
was determined for the various systems. The eta(o) of INM/EPO, INM/PVPVA, and
INM/PVPK30 systems were found to be significantly lower as compared to pure
polymer, indicating good miscibility of drug and polymers. INM/P188 mixtures showed a
higher eta(o) compared to pure polymer indicating partial miscibility of drug and
polymer. With respect to E(a), INM/EPO mixture showed an increased E(a) according to
drug concentration increase, suggesting antiplasticization effect of the drug. The mixtures
of INM/PVP-VA showed a decrease in the E(a) with the increasing drug concentration
suggesting a plasticization effect of the drug. Considering these findings, a model was
developed to correlate the zero rate viscosity to the motor load for hot-melt extrusion
process [65].
The state of solid dispersions dissolved in dissolution media was investigated by
Tho I et al. Ritonacir-PVPVA-Span 20 solid dispersion was prepared using hot-melt

27

extrusion. Melt extrudates with and without ritonavir were studied. Nano/microdispersions formed for both drug containing and placebo system when the melt extrudate
dissolved in dissolution media. The Nano/micro-dispersions are sensitive to anions and
may form association, aggregation or flocculation overtime. The conclusion of such study
was that the drug delivery system itself plays a key role for the formation of the observed
particles [66].
Application of hot-melt extrusion method for thermo sensitive drug remains a
challenge due to exposure to high temperatures. Three cellulose based polymers with
relative low Tg; HPMC 3cps, HPMCP and HPMCAS were selected to prepare solid
dispersions with a poorly water soluble drug, NVS981, which degrades upon melting at
165 °C. Two different drug loads of 20 and 50% (w/w) were studied in each polymer
system. Solid dispersions with 50% (w/w) drug loading were easier to process in the melt
extruder compared to that of 20% (w/w) drug loading. High drug loading introduced
better plasticizing effect to the system. Among the three polymers, HPMCAS was found
to be the best one as it was easily processed and provided stable solid dispersions after 3
months storage at accelerated stability conditions with enhanced dissolution [67].
Hot melt extrusion (HME) and KinetiSol Dispersing (KSD) which is a new
fusion-based process developed to rapidly form solid dispersions by imparting high shear
and frictional forces were utilized to prepare solid dispersions of a BCS class II
compound ROA with Eudragit L100-55 and HPMCAS. The compound was chemically
thermal sensitive and unstable in acidic pH. Since the amorphous form can’t be obtained
by hot-melt extrusion, the KSD process was investigated to reduce the decomposition of
ROA while rendering compositions amorphous. The results of the study demonstrated
that KSD is an effective method of forming dissolution-enhanced amorphous solids [68].
A novel hot melt extrusion strategy has been proposed to handle thermal sensitive
drugs. Lakshman JP et al combined spray drying and hot-melt extrusion together to
prepare solid dispersion. The high melting point drug was first processed to get
amorphous form using a solvent evaporation method by spray drying technique. Polymer
and amorphous drug mixture were further processed using a hot-melt extrusion. This
process bypassed the exposure of thermal sensitive drug to high temperature. In the hotmelt extrusion process, the drug substance itself acted as the plasticizer for the polymer.
Homogeneous dispersion in the matrix and subsequent enhanced dissolution of the drug
were further improved by adding surfactant in the system. This novel system showed
higher bioavailability than formulations containing the crystalline API. In an accelerated
stability test, no crystalline drug was observed [69].
Although many successful commercial products of hot melt extrusion solid
dispersion have shown the distinguished benefit of this technique, a critical prerequisite
to the manufacturing process which is the miscibility of the drug and its carrier polymer
is still a limitation factor for hot melt extrusion application. The drug has to be dissolved
in the carrier polymer in the molten form, when the melt is cooling down, the drug will
be dispersed in the carrier at molecular level. Another limitation to the hot melt method
is the thermostability of drug and polymer. Lower melting point of the drug-carrier
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system is preferred. Generally, drug is more stable when it was treated at lower
temperature. If high temperature is needed in the process, drug and carrier have to be
thermal stable and do not decompose or evaporate. Many drug candidates are thermally
unstable; they will be decomposed upon high temperature or the temperature near their
melting point. In this case, an alternative method, solvent evaporation method has been
studied and applied to make solid dispersion [70]. The major and commercial process is
spray drying. Several commercial solid dispersion drug products are using this technique
which has been listed in Table 2-1. The principle and technical aspects will be discussed
in detail below.
2.3.2 Spray drying
As an alternative method for hot melt extrusion, solvent evaporation method is
also commonly used in solid dispersion preparation. Spray drying technique has been
widely used in food industry for milk powder production, cartridge manufacture, and
pesticide production. In the pharmaceutical industry, it is poplar in pharmaceutical
excipient or co-processed excipient manufacture.
The basic steps for preparing solid dispersion using spray drying include:
1. Dissolving the API, polymer carrier and any other desired adjuvants in a common
solvent; 2. Atomising the liquid into fine droplets; 3. Rapidly removing the solvent from
the liquid droplets as they fall through the drying chamber; 4. Collecting the resulting
powder; and 5. Further drying the powder to remove residual solvents. 6. The final step
was tableting or encapsulation. The Figure 2-4 showed this process.
A common spray drying instrument consists of sample feeding system, heating
unit, atomization unit and sample collection unit. The machine made by different
manufacturer has different design [71]. The schematic diagram of a basic spray drier is
shown in Figure 2-5. The atomization unit is the key part of a spray dryer. Commonly,
two fluid nozzle, pressure nozzles and rotating wheel atomizers are available to meet the
requirement of laboratory scale, pilot scale and manufacture. For laboratory application,
two-fluid nozzle is often used. Pressure (hydraulic) nozzles are often installed for
manufacture because it is the most efficient way in atomization. Besides, rotary atomizers
are also available for pilot scale.
When preparing solid dispersion using spray drying, a closed system is usually
selected since the solvent can’t be evaporated into air. The commonly used solvents
include ethanol, acetone, ethyl acetate, tetrahydrofuran, methanol, dichloromethane,

Figure 2-4.

Scheme of solid dispersion preparation using spray drying technique.
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Figure 2-5.

Components of spray dryer.

water and various combinations of these. Typical polymers include PVP, PVPVA, and
HPMC, HPMCAS and other HPMC derivatives and acrylate copolymers. Addition of
surfactants to stabilize the common solvent system is not uncommon [71]. The major
advantages of spray drying technique are fast process time, the ability to work with
thermal sensitive APIs, flexibility of process various solvent systems with various
surfactants and polymers. After solvent is removed, the drug dispersed in the carrier
matrix homogeneously at molecular level. In spray dried solid dispersions, particle size
reduction, wettability enhancement and amorphous form acquisition of hydrophobic drug
are obtained in one step. The consumption of organic solvents thus adding the costs and
the followed requirement of residual removal are the major disadvantages of this
technique.
The properties of spray dried solid dispersion, such as density, flowability and
residual solvent can be controlled by adjusting process parameters, such as nozzle type
selection, inlet temperature, outlet temperature and carrier gas volume. Particle size and
distribution decide the flowability of spray dried powder which can be optimized by
selecting nozzle. The two-fluid nozzle usually produces small particles, the size is around
2-30µm, larger particles are produced by pressure nozzles; the higher inlet temperature
can shorten the whole process time and the drying time, at the same time, residual
solvent must be controlled at a low level. If the inlet temperature is too high, the outlet
temperature will also be increased which may induce a sticking problem in the spray
drying process when the outlet temperature is higher than the Tg of sample system or
melting point of compound. However, low outlet temperature will keep more residual
solvent in the spray dried powder which will be as plasticizer to reduce the Tg of solid
dispersion system. Carrier gas provides heat energy to dry the sample, it can be air when
sample has no organic solvent or can be inert gas, such as nitrogen gas when the sample
contains organic solvent. The volume of carrier gas will affect the product yield.
Generally, this parameter needs to be optimized according to different type of spray
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drying instrument [71]. In summary, optimization of spray drying process is an integrated
process; decision for each parameter will affect other parameters. Considering the final
property of solid dispersion powder, all parameters will be optimized and decided
together. The commercialized drug product manufactured by spray drying method was
shown in Table 2-1. The articles of spray dried solid dispersion published in recent years
are reviewed as follows:
A ternary system: solid dispersions griseofulvin, PHPMA and PVP have been
prepared using spray drying technique. Acetone and water or acetone and methanol were
selected to dissolve drug and polymer. The solvent system affected the properties of solid
dispersions significantly. Thermal analysis was done for the spray dried solid dispersion
powders, high Tg was about 103 degrees C for the acetone/methanol system, while for
acetone/water system, the Tg was 83 degrees C. This is because the conformational
variations of the polymers in solution prior to spray drying. The effect of drug and
polymer concentration on the properties of solid dispersions was also studied. A lower
relaxation rate was found to solid dispersions which spray dried from dilute drug-polymer
solution [72].
Caron V et al investigated the sulfathiazole (STZ)/ PVP and sulfadimidine
(SDM)/PVP solid dispersions preared by spray dying and co-milling method. Multiple
analysis techniques have been applied to characterize the two solid dispersions. Both
spray drying and co-milling method can produce homogeneous glass solutions for the
two model drugs and the value of T(g) for a particular API/PVP ratio did not depend on
the processing technique used. According to the Gordon-Taylor equation, the interaction
between drugs and PVP are not stong which was indicated by the consistent results of
measured Tg and predicted Tg and the variation of T(g) versus concentration of PVP was
monotonic for all the systems. Amorphous SDM can be obtained on spray drying but not
amorphous STZ. Flory-Huggins model was applied to calculate the miscibility of two
APIs and PVP. The results showed that the two APIs have similar miscibility with PVP.
Intrinsic dissolution studies in aqueous media revealed that dissolution rates of glass
solutions were the fastest no matter the preparation method. A conclusion was made that
co-milling can significantly enhance the dissolution of some poorly soluble drugs to a
similar magnitude as co-spray dried systems [73].
A review article covered how the particle formed by spray drying technique from
theory to practice. Some application examples in pharmaceutical industry -- low density
particles, composite particles, microencapsulation, and glass stabilization -- are
discussed, with specific emphasis on the underlying particle formation mechanisms and
design concepts [74].
An application of poly(2-hydroxyethyl methacrylate) (PHEMA) hydrogel in
solid dispersion has been studied. Three drugs: diclofenac sodium, piroxicam and
naproxen are selected as model drugs. XRD, DSC and FTIR are used to characterize
these solid dispersions and stability under various conditions. The results show that as
high as 30% drug loading is acceptable, above that will induce amorphous to crystalline
transition. During storage, high RH% will increase the recrystallization rate duing storage
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for any drug loading. The FTIR result indicates that hydrogen bonding presents among
drug and polymer. Dissolution rate of the three model drugs in solid dispersion increased
compare to their physical mixture. A conclusion has been made that the PHEMA can be
used as potential solid dispersion carrier to enhance drug dissolution rate and futher
bioavailability [75].
Solid dispersion piroxicam –PVP prepared by spray drying and supercritical CO2
fluid method has been studied by Ke Wu et al. DSC, FTIR and XRPD were applied to
characterize properties of solid dispersion. Multiple techniques showed amorphous form
was presnt in the binary system with 20% drug loading. The dissolution rate of piroxicam
in solid dispersion prepared by supercritical CO2 fluid increased significantly compared
to that of API itself. From the investigation, the author drew the conclusion that PCA
(supercritical fluid CO2) processing could be an effective alternative method to prepare
solid dispersion [76].
In the early stage of solid dispersion research, 1970s’ to 1980s’, PEG and PVP are
the most common polar polymers. After that, semi-synthesized polymers, such as HPMC
or its derivatives were used and studied as solid dispersion carriers. Besides PEG and
PVP, HPMC became the third type of polymer that was applied in commercial drug
products. Bend research Inc. recently published an article reviewed more than one
hundred compounds that form solid dispersion with hydroxypropyl methylcellulose
acetate succinate (HPMCAS) by spray drying method. These spray dried dispersions
(SDDs) kept supersaturation and amorphous drug/polymer colloids in in vitro dissolution
determinations and were found to have large bioavailability increases in vivo. At the
same time, those compounds can remain amorphous form during storage. This large scale
solid dispersion test proved that the spray drying technique and HPMCAS is a successful
combination for solid dispersion preparation [77].
2.3.3 Supercritical fluid extrusion
Besides hot-melt extrusion and spray drying method, supercritical fluid has been
also introduced as a solid dispersion preparation method. Supercritical fluid is neither gas
nor liquid. However, it has the properties of gas and liquid at the same time. Under
certain temperature and pressure, gas can form supercritical fluid which has the high
density and low viscosity. The special fluid has the solvent capacity to extract constitutes
from plants according to the polarity. Upon the adjustment of pressure, the supercritical
fluid will extract material from low polarity to high polarity and then enter the separation
unit, where supercritical fluid is separated with the extraction and then go to collection
unit for recycle. Carbon dioxide (CO2) is the most commonly used media in supercritical
fluid technique. In solid dispersion preparation, compound and polymer will be first
dissolved in common solvent, then the sample is treated by CO2 supercritical fluid,
solvent will be extracted and removed by CO2 fluid and the solid dispersion powder is
separated and precipitated from solvent. The common solvent and CO2 will be further
separated for recycle. The advantage of CO2 supercritical fluid method is its low cost and
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environmental friendly, the solvent residual in solid dispersion powder is less than that of
spray drying method.
Rodier et al prepared eflucimibe-γ-cyclodextrin co-crystal solid dispersion using
supercritical fluid extraction method. Both the solubility and the dissolution rate were
improved. Eflucimibe and cyclodextrin have been dissolved in DMSO and then treated
with supercritical carbon dioxide, solvent was removed. Then the co-crystal was kept
under supercritical condition for several hours, then the solid dispersion was treated a
second time by supercritical carbon dioxide to remove residual solvent. The three step
operation process made efludimibe homogeneously dispersed in γ-cyclodextrin. The
properties of solid dispersion are not sensitive to the operation parameters [78].
Won et al. have prepared felodepine solid dispersion using conventional solvent
evaporation method, CSE and supercritical anti-solvent method, SAS. The carrier
includes HPMC and surfactant. Felodepine is in amorphous form no matter the
preparation method. The SAS method is better than CSE method after comparing the
properties of the solid dispersions. The solid dispersion prepared by SAS method has
smaller particle size, better flowability, less residual solvent, higher solubility and faster
dissolution rate [79].
2.3.4 Other methods
Co-grinding and electrostatic spinning method are also used to prepare solid
dispersion [80, 81].
2.4 Characterization Techniques
Many techniques are available to contribute information for explanation of the
physicochemical phenomenon of solid dispersions. Generally, a combination of two or
more techniques is required to characterize a solid dispersion system. The advantages and
disadvantages of each technique are briefly discussed below.
2.4.1 Powder X-ray diffraction (XRPD)
XRPD is applied to determine whether crystal or amorphous form exist in solid
dispersion, it can also quantify crystalline degree if the crystalline standard curve can be
made [82]. X-rays are considered radiation in the electromagnetic radiation spectrum, the
wavelength of X-rays is around 0.01 nm to 10 nm. Crystalline material has a
characteristic atomic structure and it will diffract X-rays in a unique pattern. The
amorphous form generally is indicated by a wide and flat peak, basically, no sharp peak
appears in amorphous material X-ray spectrum. Based on the physical state of various
materials, XRPD can also be used in measurement and prediction of crystal size and
shape, protein structure characterization, etc.
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XRPD is a straightforward method to distinguish a crystalline from an amorphous
system. Its sensitivity is around 5%. In solid dispersion characterization, it is often
combined with other techniques to characterize the phase separation, crystalline degree
even the size of crystal. When determining the crystalline degree, a series standard
sample needs to be prepared: 5 to 7 crystal concentration points are needed to construct a
wide range standard curve with a determined limit of quantitation. Using a calibration
curve to quantify the crystalline content is similar to that of other chemical quantify
methods, such as HPLC.
Anthony Severdia et al used XRPD to determine the content of crystalline form I
in crystalline form II. They mixed form I and II at different ratio and then constructed
calibration curve using peak area or peak height. When they used peak area to construct
standard curve, the R2 was better than that of peak height, but the difference was not
large. The author also quantified the content of form I in form II using an NIR method.
Basically, both XRPD and NIR methods can be used in crystalline quantitive analysis,
but when the crystal content was lower than 5%, the accuracy of measurement will be a
problem [83].
2.4.2 Thermal analysis methods
Thermal analysis tools are often used in solid dispersion characterization.
Differential scanning calorimetry, DSC and thermal gravimetric analysis, TGA are most
commonly used. DSC can measure many thermal transition phenomena including
melting point, glass transition point, or recrystallization transition, etc. These
measurements provide qualitative and quantitative information that about physical and
chemical changes that involve endothermic or exothermic processes or change in heat
capacity. Modulated temperature DSC is derived from conventional DSC. The
temperature is continually increasing in sinusoidal modulation (oscillation) way which is
different from the linear fashion of traditional DSC. Thermal events respond differently
to the oscillation heating rate. In MDSC, glass transition temperature can be easily
observed and assigned. A disadvantage of MDSC is it is time consuming: one hour or
longer time is needed for a typical MDSC data collection [84].
TGA measures mass change of a substance as a function of temperature while the
substance is subjected to a controlled temperature program. If the substance contains a
volatile fraction, the mass will be lost when the temperature is high enough. TGA is also
combined with DSC to differentiate the true melting and decomposition. If a sample has
the melting combined decomposition, DSC can only give an endothermic melting peak or
exothermic peak. As for the exothermic peak, it is generally assigned as a decomposition
peak; however, to confirm this assignment and remove the possibility of operation error,
sample is further tested by TGA. The observed weight loss curve shown in the same
temperature range on TGA will verify the results of DSC.
In nearly every published article related to solid dispersion, DSC has been applied
as a routine tool to measure the glass transition temperature, melting point; to distinguish
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phase separation as well as to quantify the content of crystal in glass solution system.
Generally, phase separation will be defined when two Tgs are found in DSC, however,
this technique has its own limitation sometimes. The Tg of separated glass domain may
not be measured by DSC if the separated domain is just about 30 nm. Newman et al using
XRPD coupled with computation of pair distribution functions (PDF) technique
successfully found a 30 nm phase separation domain in indomethacin-PVP binary glass
solution system [85].
2.4.3 Fourier IR
Fourier transform infrared spectrum is a specific character for compound.
Commonly, the spectrum of a compound before process and after process will be
compared to see if there is difference that can be found in the spectrum profile. The
spectrum of crystalline and amorphous state of a compound usually reflects differences in
FTIR. Based on this point, FTIR is applied together with other techniques to characterize
solid dispersions. The advantages of this technique include the small sample size (about
several micrograms), quick test time (several minutes) and relatively inexpensive and
easy to operate.
FTIR was used to study the effect of compression on miscibility of naproxen-PVP
K25 solid dispersions. FTIR analysis showed the unchanged profile of drug in solid
dispersion upon compression when drug loading was 20%. While, when drug loading
was increased to 30% and 40%, phase separation was induced by compression pressure
(565.05MPa). The altered IR spectral profile and two Tg in DSC confirmed this point
together [86].
Qi et al applied Attenuated Reflection Fourier Transform IR (ATR-FTIR)
combined thermal and imaging technique to identify the paracetamol-Eudragit® E solid
dispersion. Spectrum evidence obtained from FTIR indicated the presence of crystalline
in 10% and 20% drug loading solid dispersion system and the major location of
crystalline was in the center of the extrudate [64].
2.4.4 Scanning differential microscopy (SEM)
SEM technique is a more direct tool to investigate solid dispersions. The
morphology of solid dispersion powders or extrudates can be easily observed visually.
Sometimes, SEM can show if the sample is crystalline or if there is phase separation.
However it is limited by the resolution. The very small crystalline may not be observed
by SEM technique.
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2.4.5 Dynamic vapor sorption (DVS)
DVS is applied to determine the moisture sorption properties of pharmaceutical
materials such as excipients, drug formulations and packaging films. These properties are
recognized as critical factors in determining the storage, stability, processing and
application performance of drug products [87, 88]. Further, organic solvent and water can
be selected to study solvate or hydrate formation [89]. It can also be used as the very
sensitive method to qualitatively and quantitatively determine amorphous contents [90].
Lesley et al. apply DVS technique to determine the amorphous content in a
micronized compound. Water and acetone are used to provide vapor pressure to construct
the calibration curve. In the experiment, 100% amorphous and 100% crystalline states are
characterized by a variety of techniques. Water vapor does not induce recrystallization
but acetone vapor can induce recrystallization. The lowest quantitative limit of this DVS
method for amorphous content determination is 0.5%. The measurement is in agreement
with the results that are determined by DSC [90].
2.4.6 Solid state NMR and 2D NMR
Solid-state NMR (SSNMR) can provide detailed structural information about
amorphous solid dispersions of pharmaceutical small molecules. In contrast with solution
state NMR, solid-state NMR (ssNMR) does not require that the sample be soluble or
form a crystal, and no specific NMR solvent consumed. Two dimensional NMR is
usually combined with this technique in solid dispersion characterization.
In SSNMR, dipolar correlation, spin diffusion, and relaxation measurements can
be separately applied or combined to characterize the structure of solid dispersions.
Observation of spin diffusion effects using the 2D H1-C13 cross-polarization
heteronuclear correlation (CP-HETCOR) can show glass solution formation. H1
doublequantum correlation experiments to probe interaction at molecular level between
polymer and drug. H1-F19 CP-HETCOR serves a similar role as CP-HETCOR for
fluorinated drug molecules. The sharpness degree of peak in NMR spectrum and
difference to its amorphous or crystal control indicate if there is glass solution formation.
Phase separation is detected using C13, F19, and Na23-detected H1 T1 experiments,
dipolar correlation and spin diffusion effect are observed to prove the molecular
interaction between drug and polymer. Two more examples: solid dispersion ternary
system of voriconazole and telithromycin with PVP and SLS are analyzed to demonstrate
the general applicability of the technique [91].
Lefort et al determines the amorphous content of trehalose in mixture of
amorphous and crystal trehalose using SSNMR. The results of C13NMR method is
compared to that of DSC technique. The good agreement of the two methods indicates
that both are useful and accurate methods for compositional characterization of powders
[92].
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2.5 Conclusion
The review summarizes several aspects of solid dispersion: concept definition,
background, commercial products, solubilization mechanisms, preparation methods,
characterization techniques. Solid dispersion is shown to be a fruitful approach to
increase the bioavailability of poorly soluble drugs because of increasing number of drug
candidates with low solubility. In addition to binary solid dispersion systems, researchers
also add surfactant or cyclodextrin in drug-polymer system to form ternary solid
dispersion for better drug performance. It has been a common strategy for poorly soluble
drug development.
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CHAPTER 3. AQUEOUS SOLUBILITY, DISSOLUTION,
PHYSICOCHEMICAL CHARACTERIZATION AND PHYSICAL
STABILITY OF SOLID DISPERSIONS OF FUROSEMIDE AND OCTENYL
SUCCINIC ANHYDRATE STARCH
The purpose of the present study was to investigate the applicabability of a cold
water soluble modified starch, octenyl succinic anhydrate starch (OSA starch) as solid
dispersion carrier to increase the aqueous solubility and dissolution rate of poorly water
soluble drug. Furosemide was selected as a model drug. The solid dispersion of
furosemide with OSA starch was prepared using spray drying technique via various
sample preparation methods: furosemide dissolved in ammonia solution (salt control),
furosemide and OSA starch dissolved in ammonia solution (amorphous dispersion,) and
furosemide dispersed in OSA starch solution (crystal dispersion). Physical mixtures (PM)
were also prepared for comparison. Three ratios between drug and OSA starch: 1:1, 1:2.3
and 1:9 w/w were selected and tested. The pH of solid dispersions, aqueous solubility and
dissolution (under pH1.2 and pH 5.8) of the drug in these solid dispersions were
evaluated compared to drug physical mixtures. Furthermore, their physicochemical
properties were investigated using SEM, FTIR, MDSC, XRPD and Dynamic vapor
sorption (DVS). Physical stability tests were done under 40 °C and 40 °C with 75% RH
for 3 months, furosemide kept its amorphous form in all samples at 40 °C, while
crystallization was found in samples treated under 40 °C 75% RH conditions. The
solubility improvement of samples was significant and in the order of: amorphous
dispersion > salt control > crystal dispersion = PM. Tablets were compressed for
dissolution test. In phosphate buffer (pH 5.8), drug released near completely in 20
minutes for all samples except PM (1:1 drug: polymer w/w). In simulated gastric fluid
(SGF, pH 1.2), the drug dissolution was tested for one hour and the dissolution rate was
as the rank of: amorphous dispersion (1:9 w/w drug: polymer) > crystal dispersion
(1:1>1:2.3>1:9 w/w drug: polymer) > PM (1:9>1:2.3 w/w drug: polymer) > amorphous
dispersion (1:2.3 w/w drug: polymer) > PM (1:1 w/w drug: polymer) > Lasix® >
amorphous dispersion (1:1 w/w drug: polymer) > salt control. At the 60 minute point,
only amorphous dispersion (1:9 w/w drug: polymer) released 80% API and the highest
amount of drug released was 65% for other samples. Using a high amount of OSA starch
in amorphous dispersions to keep a supersaturation state of furosemide in acidic
conditions was thought to be the principle factor for dissolution improvement. From the
study, OSA starch can be applied as a solid dispersion carrier with controlled humidity.
Both the preparation method and starch amount play critical role in developing a binary
solid dispersion system for a poor water soluble drug.
3.1 Introduction
Solid dispersion is one of the drug solubilization techniques that is utilized to
formulate poorly water-soluble drugs. It is a well-established method that has
successfully brought several poorly soluble drugs to market, e.g. telaprevir, etravirin and
verapamil, etc. The major preparation method includes melting and solvent-evaporation
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method [93]. Basically, drug and polymer mixture is heated until it melts and then
quenched cool to get solid dispersions or dissolve drug and polymer in a common solvent
and then spray drying the solvent to get solid dispersion. Moreover, another method:
surface-attached solid dispersion has been developed to avoid using organic solvent.
Drug is dispersed in polymer water solution and remains in crystal form with small
particle size upon evaporation of water [94]. This solid dispersion could increase
solubility and bioavailability of drug and at the same time, however not change its
crystalline state. The major mechanisms of solid dispersion techniques contribute include
one or more of the following: enhanced water wettability, particle size reduction, reduced
aggregation and agglomeration and enabling creation of an amorphous state [42, 43].
OSA starch is made by esterification of already hydrolyzed and depolymerized
starch and anhydrous octenylsuccinic acid under alkaline conditions [95]. OSA treated
starches contain hydrophobic octenyl side chains which impart an emulsifying capability
to the starches. Thus, the OSA starch bears an amphiphilic property that has been widely
used for many years for flavor encapsulation and emulsifier for beverage emulsions. It
has good cold water solubility, low viscosity of solution at high solid content, nonhygroscopic character, bland taste, non-reactivity and low cost. All these advantages
make it a good spray drying carrier material [96].
When OSA starch is used in solid dispersions via spray drying technique, the
hypothesis is that the drug dissolved in starch solution. When water evaporates via spray
drying, the drug will be solidified together with starch and mostly the drug is in
amorphous form because the very fast spray drying process (seconds) prevents drug
crystallization. In the spray dried powder, the drug won’t be distinguished from the starch
matrix. In this system, starch is homogenously distributed in the matrix thus prevents
drug crystalline growth. When drug is dispersed in starch solution, starch will encapsulate
drug particles to complete the microencapsulation process. Micro-scale drug particles
will be retained in the starch matrix. These properties will be helpful in enhancing drug
solubility and dissolution rate.
Furosemide is a loop diuretic that acts on the kidney to remove excess water and
electrolytes into urine, thus reducing the body fluids. Furosemide was used to treat
hypertension, congestive heart failure and edema [97]. Furosemide is a BCS class IV
drug. It is often selected as model drug to test new formulation techniques or as candidate
for drug optimization because of its low and various bioavailabilities [97, 98]. Many oral
formulations have been used in order to increase solubility of furosemide such as
cyclodextrin complexes [99-101], dendrimer complexes [102], self micro-emulsifying
drug delivery systems [103], mesoporous silicon microparticles [104], solid dispersion
with various carriers [105-108] have been investigated.
The purpose of present study is to explore the applicabability of OSA starch as
solid dispersion carrier in the pharmaceutical field. Since it is a good spray drying agent,
spray drying technique is one of the major methods for solid dispersion preparation, and
because of its amphiphilic property, OSA starch is theoretically considered as a solid
dispersion carrier. Thus, experiments are conducted to evaluate the effect of OSA starch,
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preparation method on the solubility, crystalline and dissolution of model drug in solid
dispersions. Solid dispersions containing furosemide were prepared as salt control,
amorphous dispersions and crystal dispersions. Solubility and dissolution were
determined for these solid dispersions. Multiple techniques have been applied to
investigate their physicochemical properties and solubilization mechanisms. Accelerated
stability test was conducted at 40 °C, controlled humidity and 40 °C, 75% RH for three
months to fully evaluate the quality of solid dispersion.
3.2 Material and Methods
3.2.1 Material
Furosemide was generously donated by Teva Pharmaceuticals (Petah Tikva,
Israel), OSA starch was provided by National Starch & Chemical (Bridgewater, NJ).
Ammonia aqueous solution was 29.4%. All other chemicals were reagent grade and used
as received without further processing.
3.2.2 Preparation of furosemide-loaded solid dispersions
A Büchi 290 mini spray dryer with 0.7mm nozzle (Flawil, Switzerland) was used
for the preparation of the furosemide-loaded solid dispersions. Since furosemide was
weak acid with pKa 3.8, its solubility is pH dependent. Ammonia solution was used to
dissolve certain amount of furosemide. All liquid samples were delivered to the nozzle at
a flow rate of 5 mL/min via a peristaltic pump and spray-dried at 120 °C inlet
temperature and 65–70 °C outlet temperature. The Q-flow was 45-50 mm and the
aspirator was set as 90-100%.
3.2.2.1 Salt control preparation
A certain amount of furosemide (2g) dissolved in 65 mL ammonia water: the
molar ratios between furosemide and ammonia were 1:1.4 (I), 1:3.6 (II), 1:6.0 (III) and
1:17.9 (IV). The ratio 1:1.4 was the minimum molar ratio to dissolve furosemide in
aqueous ammonia. Then these aqueous solutions were spray dried to get ammonia salt
control samples. These salt solid dispersions were vacuum dried overnight to remove
residual ammonia and then store in refrigerator for fully characterization. By aid of a
basic environment that ammonia provided, furosemide and OSA starch can be easily
dissolved in water at the same time. This is the critical step for solid dispersion
preparation using solvent-evaporation method.
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3.2.2.2 Solution solid dispersion preparation (Soln. SD)
Three ratios (1:1, 1:2.3 and 1:9 w/w) between furosemide and OSA starch were
selected to prepare amorphous solid dispersions. Ammonia solution (29.4%) 0.5 ml was
added to 35 ml water, then 1 g furosemide was added into ammonia solution, then OSA
starch 1 g, 2.3 g and 9 g were added to the furosemide ammonia solution separately. In all
amorphous dispersion samples, the ratio between furosemide and ammonia was 1:1.4
(mol/mol). After stirring and mixing well, these colloid solutions were spray dried to get
powder. These solid dispersion powders were stored at refrigerator for characterization
after drying in vacuum oven overnight.
3.2.2.3 Suspension solid dispersion preparation (Susp. SD)
OSA starch 1 g, 2.3 g and 9 g dissolved in 35 ml water, and then 1 g furosemide
was added into starch solution, less than 5% PEG 400 was added into the liquid as
dispersion stabilizer to prevent precipitation during spray drying process. Then the liquid
was converted to powders after spray drying. Then the same process step was applied for
the powder as former samples.
3.2.2.4 Physical mixture (PM)
OSA starch 1 g, 2.3 g and 9 g were mixing with same amount of furosemide using
liquid-solids blender (type: LB-4455, The Patterson-Kelley Co, east Stroudsburg, PA.)
for 3 min each. Then store in regenerator for further characterization.
3.2.3 Aqueous solubility measurements
Excess amounts of furosemide (about 10 mg) for salt control, amorphous
dispersion, crystal dispersion powders and physical mixtures were added into triplicate 20
ml screw-capped vial that contained 10 ml R.O. water (pH 6.2). The vials were vortexed
for 30 seconds at 1000 rpm, and then put on a shaker, shaking at room temperature (25
°C ± 1 °C) for 24h, centrifuged at 3000×g for 10 min (Eppendorf, NY), filtered through
a membrane filter (0.22 µm) and then diluted to proper concentration for analysis by
HPLC. The HPLC system was a HP 1100 system together with a Nova-Pak® C18
Column (Waters, 4 μm, 150 mm Χ 3.9 mm, i.d.) and a UV Detector. The mobile phase
was 10 mM potassium phosphate monobasic and methanol (60/40, v/v), pH adjusted to
2.5 by phosphoric acid. The flow rate was 1 ml/min, injection volume was 10 µl and the
wavelength was 276 nm.
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3.2.4 pH measurements
After spray drying and vacuum oven drying, free ammonia should be removed
from samples because of the low partial pressure of ammonia. For API, salt control, solid
dispersion and physical mixture, a 1% dispersion (w/v) was prepared in triplicate for pH
measurement to determine the effect of pH on solubility of the solid dispersions. The pH
of liquid samples before spray drying was also measured.
3.2.5 Shape and surface morphology
The photomicrographs of furosemide, OSA starch, solid dispersion powders and
physical mixture were obtained by environmental scanning electron microscope (SEM)
with backscattered electron detector (QUANTA™, FEI, Hillsboro, OR). Powders
were mounted on a double faced adhesive carbon tape; then low vacuum (50 and 80 Pa)
was applied in the chamber, allowing us to observe the powders without further
treatment. The voltage was 10kV, working distance was 10 to 8 mm, spot size was 3 and
the magnification was from 250X to 5000X.
3.2.6 Crystallinity, thermal and spectroscopic properties
The crystallinity of the API, OSA starch, physical mixture and solid dispersions
were assessed by X-ray powder diffraction (XRPD). The experiment was conducted at
ambient temperature using monochromatic Cu K radiation at 40mA and 40kV in the
range of 5°  2θ  30° with an angular rate 0.02° / s. Thermal properties of these samples
were obtained by a differential scanning calorimeter with modulated temperature (DSC
Q2000, TA Instruments, DE). The samples of around 5 mg were placed in aluminum
pans and were tested by a modulated temperature DSC program: equilibrated at 30 °C,
scanning from 30 to 250 °C with a heating rate of 2 °C /min, a period of 60 s and
amplitude of ±0.32 °C. Fourier transform-infrared spectra were obtained on a FT-IR
spectrometer (Perkin Elmer, Waltham, MA). The sample powder was measured directly
with no additional preparation.
3.2.7 Humidity effect on solid dispersion and Dynamic Vapor Sorption (DVS)
DVS experiment was conducted to characterize if there is humidity induced
crystallization and hygroscopicity of samples. The experiments were undertaken using a
Dynamic Vapor Sorption apparatus (DVS, Surface Measurement Systems, London, UK).
The instrument has a microbalance inside a temperature-controlled cabinet. Temperature
was kept at 25 °C for all experiments with dry nitrogen gas purge at 200 ml/min. The rate
and extent of water uptake determined over a range of 0 to 90 to 0% RH cycle. The
equilibrium was assumed when the weight change was less than 0.02% w/w. The time for
each sample varied from 5-10 hrs.
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For control I, one more DVS experiment was done to demonstrate humidity
induced recrystallization from a amorphous furosemide salt. The sample was treated
under dry condition (0%RH) for 1h, and then was treated with constant moisture
(75%RH) under isothermal (25 °C) environment for 5 hrs. Then the sample was collected
to run MDSC or DVS with a fixed relative humidity (75% RH for salt control I).
3.2.8 Physical stability
Solid dispersion physical stability was performed at 40 °C for 3 months, at 40 °C/
75% RH for 2.5months and ambient condition (25 ±5 °C, 25-55%RH) for 4 months.
XRPD was performed as 2.6 to observe if crystal grew in these samples.
3.2.9 Dissolution
Simulated gastric fluid (pH 1.2) and phosphate buffer (pH 5.8) were prepared for
dissolution tests. The experiments were conducted at 37 °C using the USP II method with
100 rpm paddle stirring speed and medium volume of 900 or 600 ml. Solid dispersions
equivalent to 20 mg furosemide plus other excipients were compressed into tablets using
Carver press (Wabash, IN). Tablet weight and formulation ingredients were shown in
Table 3-1. Compression force was 1.1 mTon; dwelling time was 3 seconds. The punch
size was 3/8 inch. The percentage drug release was monitored using an on-line UV-Fiber
optic dissolution system (Dynamic Dissolution Monitor™ system, Woodbridge Scientific
LLC, CT).
Table 3-1.

Ingredients of two tablet formulations.

Formulation I

%

Formulation II

Solid dispersion powder

64.5

Solid dispersion powder

%
64.5

Starch 1500

32

MCC

27

3
Ai-Di-Sol
0.5
MgSt
5
Colloid silicon dioxide
Tablet weight: 35mg, salt control I, 65mg, corresponding to solid dispersion (50% drug
loading), 105mg, corresponding to solid dispersion (30% drug loading), 310mg,
corresponding to solid dispersion (10% drug loading).
Ai-Di-Sol
MgSt

3
0.5
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3.3 Results and Discussion
3.3.1 Aqueous solubility and 1% dispersion pH
Aqueous solubility of all samples was shown in Figures 3-1, 3-2 and 3-3. In each
figure, the solubility of API was also shown. The summary of all the solubility and pH of
1% dispersion (w/v) was shown in Table 3-2. For salt control samples, four molar ratios
between furosemide and ammonia were screened to select a proper ratio that can increase
the solubility of API to the highest degree. Ammonia acted as a base toward water to
form a mixture of the ammonium and hydroxide ions. Then the oxygen of furosemide
will combine ammonium ions to form salt. The reaction can be representing as
Figure 3-4.

Equilibrium solubility
(µg/ml)

Theoretically, the reaction of furosemide and ammonia was in 1:1 molar ratio. But
practically, the molar ratio 1:1.4 was the minimum amount of ammonia needed to
dissolve furosemide. When amount of ammonia increased, the solubility increased, too.
However, the solubility did not continually increase when the molar ratio increased from
1:6 to 1:17.9. The molar ratio that can enhance solubility most should be in the range of
1:1.4 to 1:6.0. From the present results, the molar ratio 1:3.6 was the best one. This
phenomenon can be explained as: at a proper ratio, furosemide formed salt with
ammonium in solution and after spray drying process, the excess amount of free
ammonia will be removed. However, the purpose of the present study was to test the
effect of OSA starch on solid dispersion, so the molar ratio 1:1.4 was selected to prepare
solid dispersion samples. The pH of 1% furosemide dispersion was about 4.8, the pH of
1% dispersion of spray dried salt control samples increased at least one unit and solubility
increased about 11 to 48 fold. The salt form contributed to enhanced solubility, and
additional discussion of the control samples will be shown later.

6000
5000
4000
3000
2000
1000
0

*
*
*

*

*
S0

CI

C II

C III

C IV

spray dried control samples

Figure 3-1. Aqueous solubility of controls.
S0: aqueous solubility of furosemide, CI: salt control I, API: ammonia 1:1.4 (mol/mol);
CII: salt control II, API: ammonia 1:3.6 (mol/mol); salt control III, API: ammonia 1:6.0
(mol/mol); salt control IV, API: ammonia 1:6.0 (mol/mol). Each value represents the
mean±SD (n = 3). * Each pair, P<0.05, student’s t test.
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Furosemide equlibrium
solubility (μg/ml)
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CI

C II
1:1
1:2.3
Amorphous dispersion

1:9

Figure 3-2. Aqueous solubility of amorphous solid dispersions.
S0: aqueous solubility of furosemide; CI: salt control I, API: ammonia 1:1.4 (mol/mol);
CII: salt control II, API: ammonia 1:3.6 (mol/mol); 1:1, amorphous solid dispersion
API:OSA starch=1:1 (w/w); 1:2.3, amorphous solid dispersion API:OSA starch=1:2.3
(w/w), 1:9, amorphous solid dispersion API:OSA starch=1:9 (w/w). Each value
represents the mean±SD (n = 3). * Each pair student’s t test, P<0.05 except samples 1:1
and 1:2.3. ** No significant difference between samples: 1:1 and 1:2.3.

Furosemide equilibrium
Solubility µg/ml
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S0
SD SD SD
1:1 1:2.3 1:9
1:1 1:2.3 1:9
Suspension dispersions and physical mixtures

Figure 3-3. Aqueous solubility of suspension solid dispersions and physical
mixtures.
S0: aqueous solubility of furosemide; Susp. SD 1:1, spray dried suspension solid
dispersion, API: OSA starch=1:1 (w/w); Susp. SD 1:2.3, spray dried suspension solid
dispersion, API: OSA starch=1:2.3 (w/w); Susp. SD 1:9, spray dried suspension solid
dispersion, API: OSA starch=1:9 (w/w); PM 1:1, physical mixture, API: OSA starch=1:1
(w/w); PM 1:2.3, physical mixture, API: OSA starch=1:2.3 (w/w); PM 1:9, physical
mixture, API: OSA starch=1:9 (w/w). Each value represents the mean±SD (n = 3).
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Table 3-2.

Summary of aqueous solubility and pH of 1% dispersion (w/v).
Samples
API
OSA starch
Control I
Control II
Control III
Control IV
Soln. SD 1:1
Soln. SD 1:2.3
Soln. SD 1:9
Susp. SD 1:1
Susp. SD 1:2.3
Susp. SD 1:9
PM 1:1
PM 1:2.3
PM 1:9

Figure 3-4.

pH
4.84
4
6.3
6.82
6.6
5.96
6.24
6.06
5.95
4.56
4.34
4.15
4.42
4.32
4.2

Aqueous solubility
(mg/ml) mean ± SD
0.096 ± 0.77
NA
1.4
4.6
3.2
1.1
7.8
8.2
19.2
0.051±3.9
0.034±1.7
0.033±3.3
0.034±0.87
0.029±3.9
0.032±2.4

Scheme of reaction between furosemide and aqueous ammonia.
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For solution solid dispersion samples, furosemide solubility was increased from
0.096 mg/ml, 1.4 mg/ml (CI) to 19.2 mg/ml (1:9). Since OSA starch was acidic, the pHs
of solid dispersions were lower than their salt control counterpart. The enhanced
solubility did not contribute to pH increase. Amorphous salt formation should be the
major contributor which will be further verified in following discussion.
For suspension solid dispersion and physical mixture, since OSA starch was
acidic and furosemide was weak acid, the equilibrium solubility of suspension solid
dispersions and physical mixture powders was similar or a little bit lower than that of
furosemide. The spray drying process didn’t alter the solubility of suspension solid
dispersion.
3.3.2 Shape and surface morphology
The photomicrographs of furosemide, OSA starch, solid dispersion powders and
physical mixture were shown in Figures 3-5 and 3-6. The SEM picture gave the most
direct way to show surface morphology and shape of spray dried powders.
The furosemide is a crystallized powder, composed of very small crystals.
OSA starch appears as an amorphous spray dried powder.
For the salt control samples: no crystals were found in control I; the two lower
ratios (control II and III) powders are composed of small spheres among which we find
occasionally a ball that has crystals. For the control IV at low magnification aspect of the
powder appears to be identical to the previous (picture didn’t illustrate) but with high
magnification we see that all the balls are made of crystals.
Solution solid dispersions: For this series, it is hard to differentiate furosemide
and starch. Compared to the control, all solid dispersion samples appeared sphere shape
and no furosemide crystals were found in those powders.
Suspension solid dispersion: For a ratio of 1:1, a suspension of furosemide in a
starch solution allows to obtain an agglomerated powder. Both products are well mixed.
The crystals of furosemide are embedded in the starch matrix. When the ratio increase the
dispersion of the crystals is not as good as before. Some particles, usually larger, contain
a lot of crystals, others consist only of starch.
Physical mixture: The crystals of furosemide and the balls of starch are well
separated.
3.3.3 Crystallinity (XRPD) and spectroscopic properties (FTIR)
The XRPD spectrum of furosemide, OSA starch, solid dispersion powders and
physical mixture were shown in Figure 3-7 and Figure 3-8.
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Figure 3-5. SEM pictures (part I) of furosemide powder and OSA starch.
Control I: salt control with furosemide to aqueous ammonia in molar ratio 1:1.4
(10000×), Control II: salt control with furosemide to aqueous ammonia in molar ratio
1:3.6 (5000×), Control III: salt control with furosemide to aqueous ammonia in molar
ratio 1:6.0 (10000×), Control IV: salt control with furosemide to aqueous ammonia in
molar ratio 1:17.9 (5000×). All controls were solid dispersion of ammonium salts of
furosemide.
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Figure 3-6. SEM pictures (part II) of amorphous solid dispersion with furosemide
to OSA starch at different ratio.
1:1, amorphous solid dispersion with furosemide to OSA starch = 1:1 (w/w) (10000×);
1:2.3, amorphous solid dispersion with furosemide to OSA starch = 1:2.3 (w/w) (5000×);
1:9, amorphous solid dispersion with furosemide to OSA starch = 1:9 (w/w) (5000×);
Susp 1:1, crystal dispersion with furosemide to OSA starch = 1:1 (w/w) (1000×);
Susp 1:2.3, crystal dispersion with furosemide to OSA starch = 1:2.3 (w/w) (1000×);
Susp 1:9, crystal dispersion with furosemide to OSA starch = 1:9 (w/w) (1000×);
PM 1:1, physical mixture with furosemide to OSA starch = 1:1 (w/w) (1000×).
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Figure 3-6.

(Continued).
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Figure 3-7. XRPD spectrum (part I) of furosemide powder and OSA Starch.
Control I: salt control with furosemide to aqueous ammonia in molar ratio 1:1.4, Control
II: salt control with furosemide to aqueous ammonia in molar ratio 1:3.6 , Control III: salt
control with furosemide to aqueous ammonia in molar ratio 1:6.0 , Control IV: salt
control with furosemide to aqueous ammonia in molar ratio 1:17.9. All controls were
solid dispersion of ammonium salts of furosemide.
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Figure 3-8. XRPD spectrum (part II) of amorphous solid dispersion with
furosemide to OSA starch at different ratio.
Soln. SD 1:1 amorphous solid dispersion with furosemide to OSA starch = 1:1 (w/w);
Soln. SD 1:2.3 amorphous solid dispersion with furosemide to OSA starch = 1:2.3 (w/w);
Soln. SD 1:9 amorphous solid dispersion with furosemide to OSA starch = 1:9 (w/w);
Susp. SD 1:1 crystal dispersion with furosemide to OSA starch = 1:1 (w/w);
Susp. SD 1:2.3 crystal dispersion with furosemide to OSA starch = 1:2.3 (w/w);
Susp. SD 1:9 crystal dispersion with furosemide to OSA starch = 1:9 (w/w);
PM 1:1 physical mixture with furosemide to OSA starch = 1:1 (w/w);
PM 1:2.3 physical mixture with furosemide to OSA starch = 1:2.3 (w/w);
PM 1:9 physical mixture with furosemide to OSA starch = 1:9 (w/w).
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Furosemide was crystalline and many sharp peaks are shown in Figure 3-7. The
near rectangle shape crystal of furosemide was also shown in the SEM picture. OSA
starch basically was an amorphous polymer and no sharp peaks shown in its XRPD
spectrum. For the four controls, they are amorphous and crystal salts. Control I and II
were amorphous salts, the ratio between aqueous ammonia and furosemide was 1:1.4
(mol/mol) or 1:3.6 (mol/mol). As for control III and IV samples, excess amount of
ammonia was added to react with API which was favorable to form pure salt and
crystallized in days.
Solution solid dispersions: For this series, all the solid dispersion was amorphous
and no sharp peaks shown on their XRPD spectrum (Figure 3-8). The ratio between
furosemide and starch was 1:1 (w/w), 1:2.3 (w/w) and 1:9 (w/w). For all the three
samples, the ratio between furosemide and aqueous ammonia was 1:1.4 (mol/mol).
Suspension solid dispersion: a suspension of furosemide in OSA starch solution
allows a liquid dispersion to be obtained. After spray drying the liquid suspension,
furosemide didn’t change its crystal form. The specific XRPD spectrum of crystalline
furosemide is shown in Figure 3-8. Increasing the starch amount didn’t affect furosemide
changing form from crystal to amorphous.
Physical mixture: furosemide kept its crystalline form in physical mixtures no
matter how much OSA starch added into their mixture.
The FTIR spectrums were shown in Figures 3-9 to 3-12. The characteristic
absorption bands of furosemide were C=O stretching of carboxylic acid group at 1670
cm-1; N-H bending at 1591 cm-1, 1561cm-1; S=O stretching of the sulfonamide group at
1318 cm-1 (asymmetric) and 1140 cm-1 (symmetric); 3350cm-1 was assigned to the NH
stretching vibration of Ar–NHCH2 and the 3282 cm−1 band to the stretching vibration of
SO2NH2 [109].
The amorphous information also showed on FTIR spectrum. In the amorphous
sample control I and II, even in control III which was less amorphous than that of control
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Figure 3-9.

FTIR spectrum of furosemide, OSA starch and four controls.
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*

**
Figure 3-10. FTIR spectrum of furosemide, OSA starch and solution solid
dispersions.
*Hydrogen bonding; **Amorphous spectrum.
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Figure 3-11. FTIR spectrum of furosemide, OSA starch and suspension solid
dispersions.
The three solid dispersions were spray dried furosemide-OAS starch suspensions.
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Figure 3-12. FTIR spectrum of furosemide, OSA starch and physical mixtures.
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I and II, the bands at 3399, 3350 and 3282 became a one wide band; at the same time,
band at 1140 cm-1 shifted to 1154-1155 cm-1and become wider; band at 1318 cm-1
shifted to 1306-1312 cm-1 and become wide, while in the crystal control IV, all above
mentioned bands do not have shift. One of the reasons for peak shift was that the atoms
arrangements in amorphous samples were loose and easily affected by surrounding
chemical environment.
Solution solid dispersions: the FTIR spectrum of this series was shown in Figure
3-9. The specific amorphous spectrum was also shown in Furo-starch Soln.1:1; Furostarch Soln. 1:2.3 and Furo-starch Soln. 1:9. Band at 1140 cm-1 shifted to 1147-1154 cm1and become wider; band at 1318 cm-1 shifted to 1307-1309 cm-1 and become wider.
The solid dispersion of furosemide-starch yielded band shifted from 1670 cm-1 to 1605 or
1606 cm-1 for C=O stretching of carboxylic acid group. It can be interpreted as hydrogen
bonding between C=O group in furosemide and –OH group in OSA starch [102].
Suspension solid dispersion: the FTIR spectrum of this series was shown in
Figure 3-10. In furosemide-OSA starch 1:1and 1:2.3 samples, C=O stretching of
carboxylic acid group at 1670 cm-1, S=O stretching of the sulfonamide group at 1318
cm-1 (asymmetric) and 1140 cm-1 (symmetric) kept its original position. Furosemide
kept its crystalline properties in FTIR spectrum.
Physical mixture: FTIR spectrum of furosemide kept its crystal properties in
physical mixtures no matter how much OSA starch added
3.3.4 Thermal analysis
DSC technique was widely used in determining melting point of crystal line
compounds. When compounds changed form from crystal to amorphous, its melting
point will disappear and at the same time, glass transition temperature will display. The
temperature modulated DSC (MDSC) can be very efficiently used in the case when the
thermodynamically reversible and irreversible processes are to be distinguished. The
glass transition was the most frequently studied example, both experimentally and
theoretically [110, 111]. The MDSC spectrum of control I was shown in Figure 3-13.
The upper one showed the Tg of amorphous control I sample and the lower one
showed the Tg of control I which has recrystallized under high moisture condition
(Sample was treated as method 2.7). For the amorphous control I, its Tg was 92.33 °C
one the reverse heat flow with heat capacity 0.3015 J/(g °C), after Tg, a thermal induced
recrystallization peak was shown on the nonreversible heat flow which further verified
that high amount amorphous content in control I; for humidity induced recrystallized
control I, its Tg was 103.59 °C with heat capacity 0.1186 J/(g °C) and no recrystallization
peak showed on its non-reversible heat flow. This point also indicated that less
amorphous content in humidity treated control I didn’t induced a measurable
recrystallization peak. Calculated the difference of heat capacity, amorphous content of
control I decreased to 38.7% comparing to that of untreated one (assuming 100%
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Figure 3-13. MDSC of control I (before and after treated with moisture).
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amorphous content) [112]. Data was shown in Table 3-3. The peak around 216 °C was
furosemide melting combined with decomposition [100].
For the other three control samples, their MDSC were shown in Figure 3-14. On
the reverse heat flow spectrum of control II, a clear Tg peak showed and followed this Tg
peak, a clear cold recrystallization peak showed at 114-140 °C. Both the symptoms gave
strong evidence of an amorphous part in this sample. This result also correlated with
those of XRPD and FTIR. As for the control III sample, a very weak Tg peak integrated
on the spectrum and no cold crystallization peak can find; similarly, no Tg and
crystallization peak can be found in control IV. The MDSC results were in good
agreement with those of XRPD. The crystal degree is Control I < Control II < Control III
<Control IV. And this point can be showed visually by SEM picture.
For solid dispersions, Tg of each sample was shown in Figure 3-15.Generally,
when people make solid dispersion, the high Tg polymer will be considered since it can
increase Tg of API. If Tg of solid dispersion is 50 °C lower than that of API, the
amorphous form can be stable theoretically [113]. But sometimes, the pure amorphous
form can still crystallized even in very low temperature. So forming solid dispersions
with high Tg polymer can stabilize amorphous state and prevent crystallization [44]. For
control I, its Tg was 92 °C, while when forming solid dispersion with OSA starch, the Tg
was increased to 104, 108 and 116 °C separately for the ratio between furosemide and
OSA starch 1:1, 1:2.3 and 1:9 (w/w). Amorphous furosemide should be more stable when
it was in solid dispersion, the results of physical stability also prove this point, and this
will be further discussed in 3.6.
3.3.5 Humidity induced crystallization and DVS
For solid dispersions, one critical issue is to keep drug substance in its amorphous
form. But this high energy metastable system is actively prone to rearrange itself to low
energy and stable systems: crystal. Moisture and heat are two major induce factors to be
considered in this transition. So, in our project, we selected thermal analysis and dynamic
vapor sorption analysis to test those amorphous systems. Thermal analysis has been
discussed in 3.4, we will focus on effect of humidity on solid dispersion.
OSA starch is hydrophilic material, and at high RH%, the material absorbed more
water vapor. From 0- 50 RH%, some water were entrapped in the starch; from 50 to 90
RH%, much more water absorbed. By the end of the experiment, 7.6% bulk water can’t
be removed and remained in the sample. For furosemide, which is very hydrophobic
material, little water was absorbed, even at RH% 90%, the mass increased only 0.14%.
The isothermal DVS plot was shown in Figure 3-16.
In this DVS experiment, we treat the amorphous sample with relative humidity
range 0 to 90%. A sharp peak in 60% to 80%RH range showed in Figure 3-17. Upon
60% RH, the amorphous part absorb moisture significantly, the mass gain from 60% RH
to 70%RH reached 3.1% and at the same time the sample started to crystallize, then water
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Table 3-3. Tg and heat capacity (Cp) of control I (before and after treated with
moisture).
Control I Tg onset
Tg
Tg end
Cp
Amorphous content
Before DVS
90.22
92.33
94.43 0.3015
100%(theoretical)
After DVS
92.58
103.59 114.06 0.1186
~38.7%

Figure 3-14. MDSC spectrum of control II, III and IV.
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Figure 3-15. Tg of OSA starch, amorphous solid dispersion 1:1, 1:2.3 and 1:9.

Figure 3-16. DVS plot of OSA starch and furosemide.
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Figure 3-17. Water vapor sorption and desorption graph of control I.
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was eliminated by the crystal as it formed a tight lattice, and the mass decreased sharply.
Then the material absorbs moisture gradually until mass reached equilibrium at 90% RH.
In desorption cycle, sample was dried little by little, then reached to -0.7% which can be
interpreted as water in original sample was removed. Since the pH of control I didn’t
change (Table 3-4), this weight loss should not be the ammonia.
When treated amorphous control I under 0% RH for 1 hour, then under 75% RH
for 4 hours, the mass change instantly upon moisture reached to 75%RH, the mass
increased around 90mins, then it become flat. In about one and half hour the moisture
induced crystallization finished. Then the sample was collected to run MDSC, results has
been discussed in 3.3.4.
The effect of moisture on solution solid dispersions was shown in Figure 3-18.
The hygroscopicity of these samples was similar in the relative humidity range of 0-40%.
The Low %RH values resulted in low vapor sorption and about 2.8% weight gain to these
samples. In the relative humidity range of 40 to 90%, solid dispersion started to absorb
water into bulk, weight gain reached to 23, 30, 40% for 1:1, 1:2.3 and 1:9 samples
separately. In desorption cycle, the absorbed water can’t be removed completely and
residual water remained in each sample. This order was highly in accordance to the starch
amount in the samples: the higher starch content, the higher water uptake. The water
uptake was higher than that of amorphous salt (control I) indicated that furosemide-OSA
starch solid dispersion was more hydrophilic and should have higher aqueous solubility
than that of amorphous salt. This point was already demonstrated by aqueous solubility
results. (Detailed solubility results in 3.1).
3.3.6 Physical stability test (XRPD)
Solid dispersion physical stability (XRPD spectrum) at ambient condition (i.e.
25±5 °C, 25-55%RH) for 4 months and 40°C for 3 months was shown in Figure 3-19.
Physical stability (XRPD spectrum) at 40°C/75% RH for 2.5months was shown in
Figure 3-20.
Solid dispersion kept its amorphous form when sample was treated under ambient
condition or 40°C. During 3 to 4 months storage time, no crystalline was detected by
XRPD technique. But when the samples were treated under 40°C/75% RH for 2.5months,
crystalline was detected in all three solid dispersions (XRPD spectrum was shown in
Figure 3-20). These phenomena indicated that furosemide-OSA starch solid dispersions
were stable to high temperature, but they are fragile to humidity. Amorphous furosemide
in solid dispersions was easily recrystallized under high moisture condition. For better
application of OSA starch in solid dispersion, it was critical to prevent high moisture
environment; specific packaging may used for this purpose
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Table 3-4. pH measurements of control I before and after water vapor sorpdesorp treatment.
Control I
Weight loss% in desorption
pH before DVS
pH after DVS

Value
0.70%
5.63±0.1
5.91±0.19

Figure 3-18. DVS graph of solution solid dispersions.
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Figure 3-19. Physical stability of solid dispersion at ambient condition and 40 °C.
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Figure 3-20. Physical stability (XRPD spectrum) of solution solid dispersion under
40 °C/ 75% RH for 2.5 months.
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3.3.7 Dissolution
For formulation I, drug released completely in 20 min for all test samples in
phosphate buffer (pH 5.8), but when drug released in gastric acid medium, the drug
dissolution slowed down. Around 80% furosemide released from amorphous solid
dispersion 1:9 at 60 min; while for the 2nd one, Lasix 20mg, it released 43% drug at 60
min point. Drug dissolution in acidic environment was in the order of solid dispersion 1:9
>Lasix 20 mg > Control I > solid dispersion 1:2.3 > solid dispersion 1:1. (Dissolution
profile was shown in Figure 3-21). Because furosemide is an acidic compound: it
remained essentially unionized when it was in acidic environment which made it less
soluble. In this case, salt form didn’t help. High amount of OSA starch can keep a
supersaturation state of drug in water which increased drug dissolution. However
amorphous solid dispersion 1:2.3 and 1:1didn’t show a benefit for drug release which
may be for two reasons. One was the non-disintegrating property of the tablet which was
caused by the stickiness of starch 1500, the other was that the starch amount wasn’t
enough to maintain supersaturation effectively. Based on the analysis, MCC was selected
to replace starch 1500 as filler to prepare formulation II to test if drug can release fast
from amorphous solid dispersion: soln. 1:1 and soln. 1:2.3.
For formulation II, drug released completely in 25 min for all test samples in
phosphate buffer (pH 5.8), which was similar to that of formulation I. While in SGF,
furosemide release was faster from soln. 1:1 and 1:2.3 after using MCC as filler than
those using starch1500 as filler. Data is shown in Table 3-5. The results proved the above
premise: the less stickiness of MCC helped the solid dispersion tablet to disintegrate and
then allowed faster drug release. Dissolution profile of formulation II was shown in
Figure 3-22. Faster disintegration can assist drug release but it was less effective in
maintaining supersaturation of the drug.
3.4 Conclusion
The natural based OSA starch can be used as solid dispersion carrier to prevent
drug crystallization, thus maintain an improved solubility and dissolution profile.
Humidity proof package material should be considered in OSA starch based solid
dispersion dosage form storage to maintain the drug in an amorphous state. Sample
preparation methods, drug loading and tablet formulations have significant effect on
solubility and dissolution profile of solid dispersions; various techniques including
XRPD, SEM, FTIR, MDSC, DVS were applied to elucidate the mechanism of solid
dispersion.
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Figure 3-21. Dissolution profile of formulation I in SGF (pH 1.2) and phosphate
buffer (pH 5.8).
Soln. SD 1:1 amorphous solid dispersion with furosemide to OSA starch = 1:1 (w/w);
Soln. SD 1:2.3 amorphous solid dispersion with furosemide to OSA starch = 1:2.3 (w/w);
Soln. SD 1:9 amorphous solid dispersion with furosemide to OSA starch = 1:9 (w/w);
Control I was amorphous furosemide ammonia salt; Lasix 20 mg was commercial
furosemide tablet, the strength was 20 mg/tablet.
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Table 3-5. Comparison of %drug release in two formulations at 60 min point in
SGF (pH 1.2).
Item
Soln. 1:9 Soln. 1:2.3 Soln. 1:1 Control I Lasix 20 mg
Formulation I
80
19.6
5.4
37
43
Formulation II
80
57
13
2
43
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Figure 3-22. Dissolution profile of formulation II in SGF (pH 1.2) and phosphate
buffer (pH 5.8).
Soln. SD 1:1 amorphous solid dispersion with furosemide to OSA starch = 1:1 (w/w);
Soln. SD 1:2.3 amorphous solid dispersion with furosemide to OSA starch = 1:2.3 (w/w);
Soln. SD 1:9 amorphous solid dispersion with furosemide to OSA starch = 1:9 (w/w);
Control I was amorphous furosemide ammonia salt; Lasix 20 mg was commercial
furosemide tablet, the strength was 20 mg/tablet.
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CHAPTER 4. PHASE SOLUBILITY OF FUROSEMIDE WITH HP-Β-CD AND
SBE-Β-CD, PREPARATION AND CHARACTERIZATION OF SOLID
DISPERSIONS OF FUROSEMIDE AND SBE-Β-CD
The purpose of the present study was to characterize the phase solubility of
furosemide with Hydropropyl-β-Cyclodextrin (HP-β-CD) and Sulfobutylether-βCyclodextrin (SBE-β-CD); solid disperson of furosemide and SBE-β-CD prepared by
kneading, spray drying and freeze drying methods. The measured aqueous solubility of
furosemide was 96 µg/ml. The phase solubility of furosemide-HP-β-CD complex was
increased from 1.3-4.1 fold respectively in the concentration of 10-100 mM HP-β-CD.
The K 1:1 and CE of the complex was 81 M-1 and 0.01 respectively. While phase
solubility of furosemide-SBE-β-CD complex was increased from 3.6-30.6 fold
respectively in 10-100 mM of cyclodextrins. The K 1:1 and CE of the complexes was 269
M-1 and 0.0318 respectively. The equilibrium solubility and drug loading of solid
dispersions were 167.9 ± 3.04 µg/ml, 165.5± 7.02 µg/ml, 115.0 ± 4.04 µg/ml, 86.0 ±
19.88 µg/ml and 12.9 ± 0.23%, 14.7± 0.33 %, 13.6 ± 0.14 %, 7.04 ± 0.72% respectively
for spray drying, freeze drying, kneading method and physical mixture ( drug: SBE-β-CD
1: 1 mol/mol). For drug to SBE-β-CD (1:2 mol/mol) for spray drying and freeze drying
solid dispersions, the equilibrium solubility was 162.6±19.8 µg/ml and 163.0±5.87 µg/ml
respectively; the drug loading were 8.1 ± 0.43 % and 7.5± 0.99 %. FTIR, SEM and DSC
further verified the complex formation. XRPD showed that drug was in amorphous form
in spray dried sample, while in other samples, drug was crystalline. The intrinsic
dissolution data demonstrated that in SGF, the drug release was in the rank of SD > KD >
FD > PM, while in the phosphate buffer (pH 5.8), the drug release was in the order of KD
> PM > FD > SD. Solid dispersion tablet dissolution showed in acidic medium, drug
release was in the order of SD > FD > KD >PM > commercial tablets, While in
phosphate buffer (pH 5.8), drug released completely in 15 min for all samples.
4.1 Introduction
Cyclodextrin is cyclic oligomer of glucose which was extracted and separated
from starch. It was widely used as drug solubilizer to enhance the aqueous solubility of
poor water soluble drugs. The shape of cyclodextrin is like a double layer cylinder. The
outside layer is hydrophilic which forms hydrogen bonds with water molecules, the
inside cavity is hydrophobic which interacts with hydrophobic molecules or hydrophobic
moiety of compound [114]. The molecular complex formation is the major mechanism
for cyclodextrin solubilization function. Commonly, α, β or -cyclodextrin are often used
which include 6, 7 or 8 glucose units. Besides original cyclodextrin, modified
cyclodextrins which include HP-β-CD and SBE-β-CD are also used in many commercial
products. The administration route is various, such as oral, rectal, buccal, ophthalmic,
intravenous and intramuscular [115]. Compared to the original cyclodextrins, the
modified cyclodextrins have benefits, such as low toxicity, high water solubility and high
solubilization capacity [116].
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Furosemide is a loop diuretic which acts on the kidney to remove excess water
and electrolytes into urine, thus reducing the body fluid. Furosemide was used to treat
hypertension, congestive heart failure and edema [117]. It has also been used as
veterinary medicine to treat horse bleeding [118]. Current drug products include tablets,
oral solution and i.v. solution. The published oral bioavailability (BA) of furosemide was
various, from 60~70% [119], or around 50% [120], or in the range 37~51% [114, 121].
Its oral absorption was quick, peak serum concentration (Cmax) was between 60 ~ 90min
[122]. A big intra-viability around 20~84% and inter- subjects viability around 20~61%
of BA were reported, too [98]. Furosemide was a BCS class IV drug which was low
solubility and low permeability [123]. Chungi et al. investigated the site-specific
absorption of furosemide in GI tract in rat model: the drug was administered to stomach
and small intestine, the rapid absorption occurred when furosemide was administered to
stomach [124]. Site-specific absorption was also studied in human, an oral immediate
release (IR) tablet was compared to an Intelisite® capsule which controlled drug release
at a specific site in GI tract. In the clinical study, the relative BA of Intelisite® capsule is
71% to oral IR tablet when furesemide was released at proximal small intestine, and there
is no absorption when drug release at colon [125]. Furosemide dissolution in the stomach
and then rapidly absorbed from upper GI tract, dissolution and solubility in stomach is
the rate limiting step for its oral absorption [115, 122, 123].
Furosemide is one of the few oral BCS class IV drug products. It is often selected
as model drug to test new formulation techniques or as candidate for drug optimization
since its low and various BA. Cyclodextrins including β-cyclodextrin (CD), dimethyl- βCD and random-methylated β-CD were investigated for use in furosemide formulations.
The solubility of furosemide is increased 3, 137 and 75 fold for βCD, dimethyl- β-CD
and random-methylated β-CD respectively when the concentration of cyclodextrin is
300mM [126]. The mechanism of complexation of furosemide and HPBCD as well as
SBEBCD are characterized using DSC, XRPD and NMR by Spamer et, al.: the
characteristic melting combined a decomposition peak shifted to higher temperature
range in DSC; the XRPD spectrums show that the degree of crystallinity is reduced;
1
HNMR and 2D-NMR (ROESY) prove that the furan ring and part of the aromatic ring
are entrapped in the hydrophobic cavity of cyclodextrin [100]. Phase solubility,
dissolution properties and permeability of furosemide and HP-β-CD complex were also
studied [119, 127, 128].
Various techniques have been used in furosemide solid formulation to increase its
aqueous solubility and dissolution rate, i.e. dendrimer complex [129], the solubility
increases around 110% per mM dendrimer added at the buffer with pH 4 to 6. The
furosemide concentration in dissolution media is around 8 µg/ml at 2 hour point and 15
µg/ml at 12 hour point under pH1.2; while drug concentration is around 12 µg/ml at 2
hour point and 18 µg/ml at 12 hour point when dissolution medium is pH5.8.
Self emulsifier drug delivery system technique has also applied to furosemide
formulations [130]: mixture of surfactant and oil is screened to form self-microemulsion
core, then furosemide is loaded at 1-10%. Solubility of furosemide in SEDDS in 1 mM
hydrochloric acid solution (0.5 ml SEDDS/250 ml) is increased to 5.31 mg/ml. Drug
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dissolution results show that the fastest drug release is around 55% and 100% at 4 hour
point in 900ml dissolution medium (pH 3.0 and pH 6.8). The amount of drug in
dissolution medium is not mentioned in article. Furosemide permeability increases as
well in SEDDS.
In addition to above techniques, solid dispersion is applied in many furosemide
formulations. At 75 min, 80% drug released in dissolution medium (pH 5.5) from 2 mg
thermal carbonization mesoporous silicon (TCPSi) microparticles with about 40% drug
loading. Furosemide permeation has been increased 5 fold when drug was loading on
TCPSi microparticles [116, 131]. In furosemide-crospovidone coprecipitating or
cogrinding samples, drug is present in amorphous form. At 60 min, drug concentration in
dissolution medium (SGF, pH1.2) reached 25 mg/L [12]. Makoto et al. investigated the
spray dried furosemide-Eudragit RS100 and RL100 solid dispersion: drug was in
amorphous form, the dissolution showed solid dispersion initial release completely in less
than 1 hour, then over time until 24h, drug concentration in dissolution medium (pH6.8)
decreased due to absorption effect of polymer resin. Solid dispersion with 25% drug
loading keeps its amorphous form for 24 days under 45°C/75%RH [132]. Shin et al. used
TPGS to make solid dispersions, and the drug was in the amorphous form. At around
30% (w/w) drug loading, the released concentration of furosemide was 40 mg/L in SGF
(pH 1.2) [12]. Another two hydrophilic polymers: HPMC E50 LV and urea were studied
to make solid dispersion. At 1 hour, around 70% and 35% drug released from solid
dispersions: API to HPMC E50 LV and urea were 1:2 and 1:5 respectively. Dosage
forms equal to 10 mg drug was tested in 900 ml SGF (pH 1.2) [133].
Changing solubility and dissolution via solid dispersion, other formulation
techniques including control release from EVA and PEG400 matrix tablet [134], tastemasking [135], multiple unit gastroretentive floating drug delivery systems [136],
solubilization using micellar solutions of ethylene oxide and styrene oxide diblock
copolymers [137] were all applied to furosemide.
In the present study, the author selected HPBCD and SBEBCD for phase
solubility experiment, and then SBEBCD was further used as carrier to make furosemideSBEBCD solid dispersion by three methods. The phase solubility, solid dispersion of
furosemide and SBEBCD including aqueous solubility, dissolution (solid dispersion and
tablet), and fully characterization (XRPD, DSC, FTIR, DVS), physical stability etc. are
presented first time.
4.2 Material and Methods
4.2.1 Material
Furosemide (Micronized) was generously donated by TEVA-TECH (Petah Tiova,
49131, Israel). Hydropropyl –β-cyclodextrin (HP-β-CD) was provided by Roquette
America, Inc. Sulfobutylether- β-cyclodextrin (SBE-β-CD Captisol®) was bought from
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Cydex Inc. (Lenexa, Kansas, USA). All other chemicals were reagent grade and used as
received.
4.2.2 Phase solubility, apparent stability constant, complex efficiency
The phase solubility test was performed as Higuchi and Connors method [138].
Excess amount of drug was added into triplicate 20ml screw capped vials which
contained 10ml various concentrations of HP-β-CD, SBE-β-CD solution and R.O. water
(pH 5.9). The vials were vortexed for 30 seconds at 1000 rpm, and then put on a shaker,
shaking at room temperature (25 ± 1 °C) for three days. At the end of each day, the
sample suspension was filtered through a 0.45um membrane filter and then diluted to
proper concentration for HPLC analysis. One way ANOVA was used to test time needed
for reaching equilibrium solubility of each complex. The HPLC system was a Shimadzu
LC10 AD together with a Nova-Pak®C18 column (Waters, 4 μm, 150 mm Χ 3.9 mm,
i.d.) and Diode Array Detector (Model SPD-M 10A). The mobile phase was 10mM
potassium phosphate monobasic and methanol (60/40, v/v), adjusted pH to 2.5 by
phosphoric acid. The flow rate was 1 ml/min and the detective wavelength was 276 nm.
The complexation constant (K 1:1) and complex efficiency (CE) were calculated
according to the Equations 4-1, 4-2 and the slope from phase solubility diagram.
K 1:1= slope / S0 (1-slope) (S0 was solubility in water)
CE= S0 · K 1:1 = slope / (1- slope)

(Eq. 4-1)
(Eq. 4-2)

4.2.3 Preparation of furosemide: SBE-β-CD solid dispersion
4.2.3.1 Kneading (KD)
A kneader (Model IKA Duplex HKD 06D, Germany) was used to prepare
furosemide loaded SBE-β-CD (1:1 mol/mol) solid dispersion. The powder mixture of
furosemide 20g and SBE-β-CD 130.6g was wetted by ethanol and water 85:15 (v/v) to
form paste and then was kneaded for 35min. The paste was dried overnight at 60 °C and
then ground into powder by using coffee grinder.
4.2.3.2 Freeze dry (FD)
Furosemide and SBE-β-CD 1g, 6.53g or 13.06g (1:1 and 1:2 mol/mol) were
dissolved in acetone / water (1:1 v/v) separately, and then mixed the two solutions to
obtain a clear sample solution. The sample solution was frozen before putting in a freeze
dryer (Labconco 4.5 liter freeze drying system) and then solvent evaporated under
vacuum to get dry powder.
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4.2.3.3 Spray drying (SD) and physical mixture
The sample solution was prepared as that in freeze dryer and then delivered to the
nozzle (0.7mm i.d.) of a Buchi 190 mini spray dryer (Switzerland) at a flow rate 5
ml/min. The inlet temperature was 70 °C and outlet temperature was 41-44 °C; the
compression air flow was about 700 L/h and aspirator was 80% (33m3/h). Physical
mixture of furosemide and SBE-β-CD (1:1 mol/mol) was well mixed by passing 60 mesh
sieve at multiple times.
4.2.4 Aqueous solubility of solid dispersion in water
The solid dispersion aqueous solubility was measured as in the method in 2.2.
Excess amount of solid dispersion powder was added to triplicate 20 ml screw capped
vial which contains 10 ml R.O. water (pH 6.0). The vials were vortexed for 30 seconds at
1000 rpm, and then put on a shaker, shaking at room temperature (25 ± 1°C) for three
days. At the end of each day, the sample suspension was filtered through 0.45μm
membrane filter and then diluted to proper concentration for HPLC analysis.
4.2.5 Solid dispersion powder characterization
Particle size distribution (PSD), surface area, true density and bulk density were
measured for drug, SBE-β-CD, physical mixture and solid dispersions. A static laser
scattering particle size analyzer (Saturn DigiSizer 5200, Micromeritics®) was used for
PSD measurements. A furosemide saturated isopropyl alcohol solution was prepared to
disperse sample powder. The experiments were performed in triplicate. The surface area
was measured with Gemini surface area analyzer (Micromeritics®) and calculated
according to BET theory by the instrument automatically. True densities were determined
using a pycnometer (Micromeritics® AccuPyc 1330) at ambient temperature. The bulk
densities were assessed using around 8ml sample powder in a 10 ml graduated cylinder.
4.2.6 Shape and surface morphology
The photomicrographs of Furosemide, SBE-β-CD, physical mixture and three
solid dispersion powders were obtained by environmental scanning electron microscope
(ESEM) with backscattered electrons detector (QUANTA FEG 200, FEI Company).
Powders were mounted on a double faced adhesive carbon tape, low vacuum (50 and 80
Pa) applied in the chamber allows us to observe the powders without further treatment.
The voltage was 10kV, working distance was 10 to 8 mm, spot size was 3 and the
magnification time was from 250X to 5000X.
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4.2.7 Drug content in solid dispersion powder
Exactly weighed amounts of solid dispersion powders triplicate in the molar ratio
of 1:1 of furosemide to SBE-β-CD were dissolved in the mobile phase and then sonicated
samples for 10 min. Then the drug content was determined by HPLC after dilute to
appropriated concentration.
4.2.8 Spectroscopic and thermal characteristics
Fourier transform-infrared spectra were obtained on a FT-IR spectrometer (FT-IR
Perkin Elmer 100 UTAR). The sample powder was measured directly and no additional
preparation. X-ray powder diffraction (XRPD) was applied to study the solid state form
of solid dispersions. Thermal characteristics of furosemide, SBE-β-CD, PM, and solid
dispersions were obtained by a differential scanning calorimeter (DSC100, Texas
Instrument, USA). The samples were placed in aluminum pans and were tested with the
following parameters: equilibrated at 30°C, ramp temperature 10 °C/min up to 310 °C for
SBE-β-CD, ramp temperature 5 °C / min up to 240 °C for furosemide and solid
dispersions.
4.2.9 Dissolution
4.2.9.1 Intrinsic dissolution
Intrinsic dissolution behavior of furosemide and SBE-β-CD binary system was
conducted to see if process methods had influence on drug release. Solid dispersion
powder which was equal to 5 mg or 20 mg furosemide for SGF (pH 1.2) or phosphate
buffer (pH 5.8) was compressed into intrinsic dissolution disks (USP Wood apparatus)
with surface area 0.5 cm2 using a Carver press (Carver Inc., IL, USA ). The compress
force was 1.1 mTon, dwelling time was 3 seconds. The dissolution medium was 600 ml,
paddle speed was set as 100rpm and other parameters and test method were same as
2.6.1.
4.2.9.2 Tablet dissolution
Simulated gastric fluid (pH 1.2) and phosphate buffer (pH 5.8) were prepared for
tablet dissolution test. The experiment was conducted at 37°C using USP II method with
50rpm paddle stirring speed and the volume of medium was 900ml. Three solid
dispersions and physical mixture equivalent to 20 mg furosemide plus 4.7% Ai-Di-Sol
were compressed into tablets. Compress force was 1.1 mTon, dwelling time was 3
seconds. The percentage drug release was monitored using an on-line UV-Fiber optic
dissolution system (Dynamic Dissolution Monitor™ system, Woodbridge Scientific
LLC, CT, USA).
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4.2.10 Dynamic vapor sorption (DVS)
The hygroscopicity of API, physical mixture and solid dispersions were analyzed
using a DVS-intrinsic instrument (Surface Measurement System) at 25 °C over the
humidity range 0% to 90% RH with nitrogen gas as the carrier gas. Sample size of
approximately 5 mg was used according to the moisture uptake properties of SBE-β-CD.
The solid dispersion sample has same drug content.
4.3 Results and Discussion
4.3.1 Phase solubility analysis
The phase-solubility diagrams (PSD) of furosemide with SBE-β-CD and HP-βCD in water were showed in Figure 4-1, with the corresponding complexation constant
(Kc) and complex efficiency (CE) values calculated from each PSD (Table 4-1). The
measured intrinsic solubility (S0) and aqueous solubility were shown in Table 4-2. The
aqueous solubility increased linearly as the function of SBE-β-CD and HP-β-CD
concentration and the PSD can be classified as the AL type. Solubility of three day’s
complex were measured and compared using one way ANOVA. Furosemide: HP-β-CD
complex needed three days to reach equilibrium state at 100mM, but for other lower
concentrations and SBE-β-CD, one day is enough to reach equilibrium solubility. Since
in many cases, the intrinsic solubility (S0) estimated from PSD can be sensitive to errors,
thus the CE become more frequently and convenient used for compare when selecting
CD in formulation development.
4.3.2 Aqueous solubility of solid dispersion in water
From the phase solubility study, the SBE-β-CD showed better solubility
enhancement effect. Thus, SBE-β-CD was selected as carrier in the preparation of
furosemide-loaded solid dispersions. In the present study, spray drying, freeze dry and
kneader methods were chosen for sample prepare. The API and SBE-β-CD ratio was 1:1
and 1:2 (mol/mol) for spray drying and freeze drying, but for kneader method, only 1:1
ratio was tested considering the large amount of SBE-β-CD consumed. The aqueous
solubility was showed in Table 4-3. Freeze dry and spray drying methods gave better
solubility enhancement effect on API, but with the increasing amount of SBE-β-CD in
solid dispersion, the solubility didn’t increase more which may further verify that
furosemide and SBE-β-CD formed 1:1 complex.
4.3.3 Solid dispersion powder characterization
The micromeritical characteristics, including particle size distribution (PSD),
specific surface area, true density and bulk density of three methods prepared solid
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Figure 4-1. Phase-solubility diagrams of furosemide.
Furosemide SBE-β-CD complex.
Furosemide HP-β-CD complex.

Table 4-1. K 1:1 and CE of phase-solubility studies of furosemide with SBE-βCD and HP-β-CD.
Excipient K 1:1 (M-1) CE
SBE-β-CD
273
0.035
HP-β-CD
81
0.010

Table 4-2.

Aqueous solubility of furosemide-CDs complex at 25 °C.

SBE-β-CD
conc. (mM)
0
10
20
30
40
50
100

Solubility of furosemide
at 25 °C (μg/ml)
41.82 ± 0.8
138.5 ± 3.0
238.0 ± 5.8
352.8 ± 10.3
462.9 ± 10.0
576.9 ± 31.6
1137.6 ± 6.0

HP-β-CD
conc. (mM)
0
10
20
30
40
50
100
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Solubility of furosemide
at 25 °C (μg/ml)
41.82 ± 0.8
119.7 ± 2.0
150.4 ± 3.1
175.3 ± 1.0
201.8 ± 3.1
228.5 ± 7.4
396.5 ± 2.8

Table 4-3. Solubility of furosemide in solid dispersion prepared with three
methods and the ratios of total solubility to the intrinsic solubility (n=3).
Preparation
method

API: SBE-β-CD
(mol:mol)

Solubility
(µg/ml)

Kneader

1:1
1:1
1:2
1:1
1:2

115.02 ± 4.04
165.50± 7.02
163.01± 5.87
167.85 ± 3.04
173.9 ± 3.57

Complex solubility/
intrinsic solubility
(S/S0)
2.74
3.94
3.88
4.01
4.15

1:1

96.9 ± 5.71

2.31

Freeze dry
Spray dry
Physical
mixture

dispersion powder were shown in Table 4-4. The PSD was in the order of PM > kneader
> FD > SD, the solid dispersion prepared using spray drying method gave smallest
particle size, thus the biggest specific surface area and least dense powders. The kneader
method gave bigger PSD, smaller specific surface area and dentist powders among the
three methods.
4.3.4 Shape and surface morphology
SEM images of furosemide, SBE-β-CD, three solid dispersion powders and
physical mixture were shown in Figure 4-2. Pure micronized furosemide was crystalline
powder, with long irregular cylinder shape; the SBE-β-CD was in spherical shape
suggested it was prepared by spray drying and the particle size was identical with results
shown in Table 4-4.
The SEM image of physical mixture pictured the fine micronized crystalline
furosemide coated on the surface of SBE-β-CD.
For the solid dispersion powders, KD powders have larger particle size than that
of SD and FD samples. The particles have holes; in these holes furosemide crystals were
highlighted and the crystalline distribution was not average. On fractures of the particles,
crystals are rare; but on certain surfaces of these fine particles, the furosemide crystals
were assembled in aggregates.
For the FD powder, fine furosemide crystals were assembled in aggregates. While
in other big blocks which showed a smooth surface on picture, it was hard to distinguish
furosemide from cyclodextrin matrix.
The spray dried solid dispersion was really small, to a large majority, much
smaller than 5 μm which was identical with PSD measurements. It’s difficult to see in
these powders the crystals of furosemide. At a magnification of 10000X, we find a few
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Table 4-4. Particle size, specific surface area, true density and bulk density of
solid dispersions, furosemide, and SBE-β-CD.

Samples

Particle size
(Median ± SD,
μm)*
5.04 ± 0.19
1293.67±79.3
90.44±2.72
46.19±0.932
7.125±0.621

Furosemide
SBE-β-CD
Kneader^
Freeze dry^
Spray dry^
Physical
123.82±2.54
miscure^
* n=3 for Particle size and bulk density.
^API to SBE- β-CD ratio is 1:1.

Specific
surface area
m2/g
3.3294
0.0864
0.4176
0.684
1.3071

True
density
(g/cm3)
0.8293
0.6603
0.7344
0.7759
0.7814

0.2636 ± 0.00056
0.5400 ± 0.0018
0.6087 ± 0.0234
0.5999 ± 0.01292
0.3117 ± 0.01161

0.3894

0.6861

0.5494
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Bulk density
(g/cm3)*

Figure 4-2. Scanning electron micrographs of furosemide, SBE- β-CD, and
furosemide SBE-β-CD 1:1 sodid dispersion prepared by different methods.
(A)furosemide (5000×), (B) SBE-β-CD (250×), (C) solid dispersion prepared by the
kneader method (1000 ×), (D) solid dispersion prepared by the freeze drying method
(1000×), (E) solid dispersion prepared by the spray drying method (5000×), (F) physical
mixture (250×). All solid dispersions were composed of furosemide : SBE-β-CD 1:1
(mol:mol).
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but they are discreet. Much of furosemide adhered to the periphery of the spray dried
spheres of SBE-β-CD but a fraction remained free which was clear displayed in physical
mixture powders.
4.3.5 Drug content in solid dispersion powders
The drug content in each solid dispersion sample was shown in Table 4-5. The
ratio between furosemide and SBE-β-CD was 1:1(mol:mol). The results accorded with
the theoretical content: 13.3% except in the physical mixture sample. The less drug
content in physical mixture was caused by API loss in sieve mixing process: the
hydrophobic API adhered on the metal screen and didn’t dilute out by SBE- β-CD.
4.3.6 Spectroscopic and thermal characteristics
FTIR spectra of furosemide, SBE-β-CD and solid dispersions were presented in
Figure 4-3. The characteristic absorption bands of furosemide at 1670 cm-1 was C=O
stretching vibration of carboxylic acid group, 1591 cm-1 and 1561 cm-1 were N-H
bending , the S=O stretching of the sulfonamide group was at 1318 cm-1 (asymmetric)
and 1140 cm-1 (symmetric) [108]. The IR spectrum of physical mixture was similar with
that of furosemide. In solid dispersios, the bands at 3399 cm-1, 3350 cm-1 and 3282 cm-1
which were N-H stretching became wide and weak which was caused by bands overlap
of SBE-β-CD or amorphous furosemide. The S=O stretching at 1140 cm-1 was shifted to
1153 cm-1 and 1670 cm-1 C=O stretching of carboxylic acid group shifted to 1175 cm-1
in spray dried sample indicated amorphous form of furosemide existed [117]. For KD and
FD samples, the IR spectrum didn’t change much compared to that of PM, API
maintained its crystal form in these samples which was also in agreement with the results
of XRPD (Figure 4-4).
The X-ray powder diffraction (XRPD) pattern of furosemide showed intense and
sharp peaks in the spectrum proved it was crystalline [117]. The SBE-β-CD was
amorphous without peak shown on XRPD. Samples prepared by kneading and freeze
drying showed sharp peaks in the spectrum, but the intensity was not as high as that of
API; the peaks indicated the crystalline form in the sample, since the drug content was
around 13% in the two samples, the intensity of peaks was lower that of pure API. No
distinguished peak shown in the spectrum of spray dried sample, the solid dispersion
prepared by spray drying was predominantly amorphous form. A small crystal peak
shown in the spectrum of physical mixture which indicated crystalline was here; and
Table 4-5.

Drug content of solid dispersion samples.

API:CD=1:1 (mol:mol)
KD
FD
SD
PM
Drug content %
14.7 ± 0.33 13.6 ± 0.15 12.9 ± 0.21 7.1 ± 0.17
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Figure 4-3. FTIR spectra of (A) furosemide (B) SBE-β-CD (C) KD solid
dispersion (D) FD solid dispersion (E) SD solid dispersion and (F) physical mixture.
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Figure 4-4. XRPD spectrums of furosemide, SBE-β-CD, furosemide solid
dispersions prepared with kneader, freeze drying and spray drying method and
physical mixture.
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low drug content (7%) didn’t incur sharp diffraction peaks. From the XRPD spectrum,
the crystalline degree was in the order of API (crystal) > Kneading ≈Freeze drying >
physical mixture > spray drying > SBE-β-CD (amorphous).
The DSC spectrum was shown in Figure 4-5. In the temperature range 207~219
°C, a sharp exothermic peak was the characteristic melting combined decomposition peak
of furosemide.14 In kneading (KD), freeze drying (FD) and spray drying (SD) solid
dispersion samples, this sharp peak disappeared and decomposition phenomena was
postponed to higher temperature range: 223~230 °C. No clear melting can be assigned to
these spectrums. Actually, the author also tried the heat-cool-heat cycle and various
heating rate (20°C, 40°C and 100°C /min) method to separate melting and decomposition
events, but based on in house condition, no clear melting point was observed. For
physical mixture (PM), the DSC was similar with that of other samples. All spectrums
showed complex formed even in simple mixture.
.
4.3.7 Dissolution
4.3.7.1 Intrinsic dissolution
The intrinsic dissolution data (showed in Figure 4-6a and b) demonstrated that in
SGF, the drug release was in the rank of SD > KD > FD > PM, while in the phosphate
buffer (pH 5.8), the drug release was in the order of KD > PM > FD > SD. In acidic
environment, the drug solubility was the limit factor for dissolution. The fastest drug
release sample was amorphous spray dried sample. After compaction, small particles
(more porosity) always form tighter compact and water penetration is slower than that of
big particles. For similar crystalline samples, the dissolution rate of KD was faster than
that of FD sample. In the phosphate buffer, dissolution rate was decided more by how
fast the water penetrated into compact. Drug released faster from the loose compact KD
and PM, but for SD and KD samples, a thin hydration layer formed on the surface of SD
and FD sample which occluded continuing fast water penetration and made drug release
slower after initial fast dissolution.
4.3.7.2 Tablet dissolution
After incorporating about 5% disintegrant, solid dispersion powders were
compressed into tablets. In acidic medium, drug release was in the order of SD > FD >
KD >PM > commercial tablets. This sequence was in accord with the solubility sequence.
An abnormal phenomenon was observed that the spray dried and freeze dried tablet did
not disintegrate which may caused by tight intra-particles physical binding. When drug
released in phosphate buffer (pH 5.8), when solubility was not the limit factor, drug
release finished in 15 mins for all samples. In this case, commercial product gave fastest
drug release due to its perfect drug disintegration performance: disintegrated completely
in 30 seconds (data is shown in Figure 4-7a and b).
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Figure 4-5. DSC spectrum of SBE-β-CD, solid dispersions and furosemide.
The ratio of furosemide to SBE-β-CD was 1:1 mol/mol.
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Figure 4-6. Solid dispersion intrinsic dissolution profile.
(a) Solid dispersion intrinsic dissolution in SGF (pH 1.2); (b) Solid dispersion intrinsic
dissolution in phosphate buffer (pH 5.8).
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Figure 4-7. Solid dispersion tablet dissolution profile.
(a) Tablet dissolution in SGF (pH 1.2); (b) Tablet dissolution in phosphate buffer (pH
5.8).
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4.3.8 DVS
Dynamic vapor sorption and desorption results were shown in Figure 4-8. The
lower line with triangle marker was sorption curve and the upper line with square marker
was desorption curve. Except for furosemide, the hydroscopicity of other samples was
similar. The Low %RH values resulted in low vapor sorption and the water was only
adsorbed on the sample surface. At 20% RH, the weight gain was in the order of SD
(4.4%) >FD (3.1%)>KD (2.9%) >PM (2.0%) > SBE-β-CD (1.6%) >API (0.028%). This
order was highly in accordance to the surface area of samples: the higher surface area,
thehigh water uptake. In the case of API, the lowest water uptake was determined by its
high hydrophobic properties. With increased RH, the sorption kinetics changed from
dominated by surface adsorption processes to bulk absorption. At 80% RH, the water
uptake order was SBE-β-CD (35.3%) > SD (33.7%) > PM (32.5%) >KD (30.8%) >FD
(29.6%) >API (0.1%). This bulk absorption was related to the amorphous property of
samples which was indicated by SEM picture and XRPD spectrum as well. The high
vapor sorption of SBE-β-CD and SD sample are fully amorphous form.
4.4 Conclusion
The phase solubility of furosemide and SBE-β-CD and dissolution of its solid
dispersions were first presented. The anionic ion SBE-β-CD in water at acidic pH can
interact with hydrogen ions which benefited the drug solubility in acidic environment
besides the function of parent cyclodextrin. In spray dried solid dispersion, the drug was
armorphous whereas in kneading and freeze dried samples, drug was crystal. When
powders were compressed into tablets, the tight physical bonding in spray dried and
freeze dried samples made it hard to disintegrate even with 4.7% disintegrant. For further
applying spray dry techniques to prepare solid dispersions for compressing tablets, a
granulation step would be needed to get proper flow and to lower interparticle bonding
for better tablet disintegration. The drug release of Lasix® was faster than those of others
at phosphate buffer but slower in SGF. This because the disintegrant in the formulation
play a critical role for drug release when solubility was not limit-factor, while in SGF, the
disintegrant didn’t help drug solubilization.
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Figure 4-8. Dynamic sorption and desorption diagram of furosemide, SBE-β-CD,
solid dispersions and physical mixture.
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